THE REGULATION OF PYRUVATE DEHYDROGENASE IN SKELETAL MUSCLE IN VIVO AND PERFUSED HEART

By

GRAHAM ROBERT WARD, M.Sc.

A Thesis
Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy
McMaster University
August 1979
MUSCLE PYRUVATE DEHYDROGENASE
DOCTOR OF PHILOSOPHY (1979)
Medical Sciences
(Blood and Cardiovascular)

McMASTER UNIVERSITY
Hamilton, Ontario

TITLE: The Regulation of Pyruvate Dehydrogenase in Skeletal Muscle in Vivo and Perfused Heart

AUTHOR: Graham Robert Ward, M.Sc. (University of Massachusetts)

SUPERVISOR: Dr. C.J. Toews

SUPERVISORY COMMITTEE: Dr. C.J. Toews
Dr. N.L. Jones
Dr. J.R. Sutton

NUMBER OF PAGES: xix; 190
ABSTRACT

The goal was to determine the physiological significance of pyruvate dehydrogenase (PDH) activation in muscle. The PDH activity was measured in small samples of muscle obtained by needle biopsy from normal volunteers. In heart PDH was measured using an isolated perfused rat heart preparation. The PDH activity was measured by determining $^{14}$CO$_2$ production from pyruvate-$^1$-$^{14}$C using whole tissue homogenates.

The total PDH (PDH$_t$) activity in human skeletal muscle was 302 ± 10 nmol/g/min. with about 40 ± 3% in the active form (PDH$_a$). With aerobic exercise (60% VO$_2$max) more than 80% of PDH was converted to PDH$_a$ within 5 min. Aerobic training did not increase the resting muscle PDH$_t$ activity (untrained 304 ± 4, trained 309 ± 8 nmol/g/min.) but it increased the PDH$_a$ from 124 ± 9 nmol/g/min. to 215 ± 15 nmol/g/min.

Muscle immobilization by arm cast for 6 weeks decreased the PDH$_a$ from 112 ± 4 to 28 ± 4 nmol/g/min. but it had no effect on the PDH$_t$ activity. Exercise following immobilization decreased the rate and the extent of PDH activation while exercise after weight training increased the extent of PDH activation.

Starvation for 24 and 48 hr. in rat heart decreased PDH$_a$ from 2768 ± 73 to 1286 ± 109- and 920 ± 149 nmol/g/min. respectively.
In the perfused heart PDH was fully activated by epinephrine (1.3 μg/ml), insulin (1 mU/ml) and high (>0.2 mM) pyruvate concentration. PDH activation was not mediated by cyclic AMP since insulin activated PDH but did not change the heart cyclic AMP concentration. Propranolol prevented epinephrine from activating PDH. Octanoic acid decreased the proportion of PDH in the active form.

In the heart a detailed study of the relationship between the rate of heart pyruvate oxidation and PDH activation was undertaken. In all experimental conditions where the rate of pyruvate oxidation was changed, parallel changes in the PDH activity was seen. The correlation between PDH activation and rate of heart pyruvate oxidation was greater than 0.92. These findings suggest that interconversion of PDH and PDH probably control the rate of heart pyruvate oxidation. A similar correlation was not seen in skeletal muscle during exercise. The calculated rate of muscle pyruvate oxidation was several fold greater than the extent of PDH activation. Although the activation of PDH regulates pyruvate oxidation in both heart and skeletal muscle, in heart this is achieved through the interconversion of active and inactive PDH whereas in skeletal muscle allosteric conversion of the active form of PDH plays a greater part.
ACKNOWLEDGEMENTS

The work on which this thesis was based was carried out in the Department of Medicine and supported by the Medical Research Council of Canada and the Ontario Heart Foundation. The author wishes to thank my supervisor, Dr. Cornelius J. Toews, for his guidance and advice while this study was in progress.

The author is also very grateful for the excellent technical assistance provided by Jeff Lin, Clark Adams, Mahendra Joshi, Rheal Leveille, Gus Matsos, Wendy Richardson, Elizabeth Head and Arlene Rasmussen.

I also wish to thank the members of the Advisory Committee, Dr. N.L. Jones and Dr. J.R. Sutton of the Department of Medicine.

I wish to extend a special note of thanks to Dr. John Sutton for taking the muscle biopsies and to Dr. Michel Rathbone for kindly doing the cAMP assays. Thanks are also extended to Dr. Duncan MacDougall of the Physical Education Department for his cooperation with certain aspects of these studies. To my typist, Mrs. Judy McClenaghan, I give my grateful thanks for her patience and cooperation.

Finally, I dedicate this thesis to my wife, Rosanne, and to my parents. I would also like to express my deepest
appreciation to them for the their continuous encouragement and understanding shown to me over the past years.
# TABLES OF CONTENTS

<table>
<thead>
<tr>
<th>Title Page</th>
<th>i</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descriptive Note</td>
<td>ii</td>
</tr>
<tr>
<td>Abstract</td>
<td>iii</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>vii</td>
</tr>
<tr>
<td>List of Tables</td>
<td>xi</td>
</tr>
<tr>
<td>List of Figures</td>
<td>xiii</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>xvi</td>
</tr>
<tr>
<td>Symbols and Units</td>
<td>xvii</td>
</tr>
</tbody>
</table>

## INTRODUCTION

1. Mammalian Pyruvate Dehydrogenase Complex         3
2. Enzyme Mechanisms                                    6
   A. Pyruvate Dehydrogenase                              6
   B. Dihydrolipoate Transacetylase                      7
   C. Dihydrolipoate Dehydrogenase                      8
3. Interconversion and Regulation of the Enzyme       9
4. Differences Between Organs in the Regulation of Mammalian Pyruvate Dehydrogenase 16
   A. Brain                                             16
   B. Adipose Tissue                                    18
   C. Liver                                             24
   D. Heart                                             28
5. General Background to Thesis                       35
# MATERIAL AND METHODS

## 1. Materials

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Animals</td>
<td>38</td>
</tr>
<tr>
<td>B. Chemicals</td>
<td>38</td>
</tr>
</tbody>
</table>

## 2. Methods

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Muscle Models</td>
<td>39</td>
</tr>
<tr>
<td>I Heart Perfusion</td>
<td>39</td>
</tr>
<tr>
<td>II Rat Skeletal Muscle</td>
<td>41</td>
</tr>
<tr>
<td>(a) Rat Training Stimulus</td>
<td>42</td>
</tr>
<tr>
<td>(b) Surgical Procedure</td>
<td>43</td>
</tr>
<tr>
<td>III Human Skeletal Muscle</td>
<td>43</td>
</tr>
<tr>
<td>(a) Short Term Exercise</td>
<td>43</td>
</tr>
<tr>
<td>(b) Long Term Exercise</td>
<td>44</td>
</tr>
<tr>
<td>(c) Short Term High Intensity Exercise</td>
<td>45</td>
</tr>
<tr>
<td>(d) Short Term Maximal Exercise</td>
<td>46</td>
</tr>
<tr>
<td>(e) Training Induced Adaptation</td>
<td>46</td>
</tr>
<tr>
<td>(i) Study 1 - Weight Training, Immobilization</td>
<td>46</td>
</tr>
<tr>
<td>(a) Training Programme</td>
<td>47</td>
</tr>
<tr>
<td>(b) Immobilization</td>
<td>47</td>
</tr>
<tr>
<td>(ii) Study 2 - Weight Training, Immobilization and Exercise - Arm</td>
<td>49</td>
</tr>
<tr>
<td>(a) Exercise</td>
<td>50</td>
</tr>
</tbody>
</table>

B. Analytical and Preparation Techniques | 51   |

I Handling and Storage of Tissue, Blood and Perfusate Samples | 51   |

II Fluorometric Analysis of Metabolites | 53   |

<table>
<thead>
<tr>
<th>Subsubsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Tissue Metabolites</td>
<td>53</td>
</tr>
<tr>
<td>(i) Adenosine Triphosphate, Creatine Phosphate</td>
<td>54</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) Pyruvate, Adenosine Diphosphate, Creatine</td>
</tr>
<tr>
<td>(iii) Lactate</td>
</tr>
<tr>
<td>(iv) Glucose</td>
</tr>
<tr>
<td>(v) Glycogen</td>
</tr>
<tr>
<td>(vi) Cyclic AMP</td>
</tr>
<tr>
<td>(b) Blood Gases and Blood pH</td>
</tr>
<tr>
<td>(c) Plasma Glucose</td>
</tr>
<tr>
<td>(d) Plasma Lactate</td>
</tr>
<tr>
<td>III Preparation of Mitochondria</td>
</tr>
<tr>
<td>IV Pyruvate Dehydrogenase Assay</td>
</tr>
<tr>
<td>V The Method for Determining the Specific Activity of Pyruvate</td>
</tr>
<tr>
<td>VI $^{14}C$ Determinations</td>
</tr>
<tr>
<td>VII $^{14}CO_2$ Production</td>
</tr>
<tr>
<td>VIII Calculations and Statistical Analysis</td>
</tr>
</tbody>
</table>

RESULTS

1. Development of PDH Assay Method | 70 |

2. Physiological Regulators of PDH Activation | 74 |
   A. Nerve Stimulation in the Rat | 74 |
      I The Effect of Sciatic Nerve Stimulation on Gastrocnemius Skeletal Muscle With a Constant Pulse Frequency and Voltage | 77 |
      II The Effect of Sciatic Nerve Stimulation on Gastrocnemius Skeletal Muscle By Varying Pulse Frequency and Voltage | 81 |
      III The Effect of Femoral Nerve Stimulation on Vastus Lateralis Skeletal Muscle By Varying Pulse Frequency and Voltage | 87 |

3. Aerobic Training in the Rat | 88 |
4. Exercise in Human Skeletal Muscle In Vivo
   A. Maximum Voluntary Isometric Contraction (MVIC) .......................... 93
   B. Progressive Exercise ...................................................... 97
   C. Intermittent Exercise ..................................................... 99
   D. Short Term Maximal Exercise .............................................. 99
   E. Heavy Resistance Weight Training,
      Immobilization in Human Triceps Brachii
      Skeletal Muscle ............................................................ 100
      I Study 1 (Group 1 and 2) ................................................ 102
         (a) Group 1 ............................................................... 102
         (b) Group 2 ............................................................... 102
            (i) Metabolites (Groups 1 and 2) ............................... 104
   F. Heavy Resistance Weight Training,
      Immobilization and Exercise in Human
      Triceps Barchii Skeletal Muscle ........................................ 106.
      I Study 2 (Group 3 and 4) ................................................ 106.
         (a) Group 3 ............................................................... 106
         (b) Group 4 ............................................................... 108
            (i) Metabolites (Groups 3 and 4) ............................... 109

5. Role of Hormonal Factors in Activating Skeletal
   Muscle PDH ................................................................. 111
   A. A Comparison Between Unstimulated and
      Stimulated Pyruvate Dehydrogenase in
      Human and Rat Skeletal Muscle ........................................ 111

6. Effect of Various Factors on PDH Activation in
   the Perfused Rat Heart ................................................... 111

DISCUSSION

1. Methodology ............................................................... 133
2. Skeletal Muscle ........................................................... 135
3. Heart Muscle .............................................................. 154

BIBLIOGRAPHY .......................... 163
LIST OF TABLES

Table 1. The effects of sciatic nerve stimulation on pyruvate dehydrogenase activation in rat gastrocnemius skeletal muscle 78

Table 2. The effects of sciatic nerve stimulation on the rapidity of pyruvate dehydrogenase activation in rat gastrocnemius skeletal muscle 79

Table 3. The activity of selected metabolites in extracts of rat gastrocnemius skeletal muscle before and after electrical stimulation 80

Table 4. The concentration of metabolites before and after sciatic nerve stimulation of 5 pulses/sec. at 5 volts in rat gastrocnemius skeletal muscle 85

Table 5. The concentration of metabolites before and after sciatic nerve stimulation of 40 pulses/sec. at 40 volts in rat gastrocnemius skeletal muscle 86

Table 6. Effect of femoral nerve stimulation on pyruvate dehydrogenase activation in rat vastus lateralis skeletal muscle before and after exercise 89

Table 7. Activity of selected metabolites in extracts of rat vastus lateralis skeletal muscle before and after electrical stimulation 90

Table 8. Effect of femoral nerve stimulation on pyruvate dehydrogenase activation in rat vastus lateralis skeletal muscle before and after exercise 91

Table 9. Selected metabolite concentrations from the vastus lateralis rat skeletal muscle before and after femoral nerve stimulation 92
Table 10. Aerobically-induced training changes of pyruvate dehydrogenase activity in rat gastrocnemius and soleus skeletal muscle with running

Table 11. The changes of pyruvate dehydrogenase activity by exercise at 50% maximum voluntary isometric contraction of various time periods in human quadriceps femoris skeletal muscle in vivo

Table 12. The effect of 50% maximum voluntary isometric contraction for various time periods on human quadriceps femoris skeletal muscle metabolites in vivo

Table 13. The effect of various types of exercise on a cycle ergometer in vivo, on the activation of human skeletal muscle pyruvate dehydrogenase

Table 14. The effect of various types of exercise on tissue metabolite concentrations in human skeletal muscle at rest and after exhaustive exercise on a cycle ergometer

Table 15. Concentrations of metabolites before and after training and immobilization

Table 16. Concentrations of metabolites before and after training, immobilization and exercise

Table 17. Muscle PDH activity in a child with severe lactic acidosis

Table 18. Muscle PDH activity in competitive athletes

Table 19. Effect of different perturbations on heart pyruvate oxidation, PDH activation and O2 consumption

Table 20. Rat heart PDH activity in various stages of starvation
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.</td>
<td>The reactions of the PDH multienzyme complex</td>
<td>4</td>
</tr>
<tr>
<td>Figure 2.</td>
<td>The scheme for PDH interconversion in mammalian tissue</td>
<td>12</td>
</tr>
<tr>
<td>Figure 3.</td>
<td>The programme for training induced adaptation of human skeletal muscle to heavy resistance weight training, immobilization and exercise</td>
<td>48</td>
</tr>
<tr>
<td>Figure 4.</td>
<td>Rat skeletal muscle PDH – PDH activity and Mg concentration per 2 min. assay time</td>
<td>71</td>
</tr>
<tr>
<td>Figure 5.</td>
<td>Rat skeletal muscle PDH – PDH active and total activity measured over time</td>
<td>72</td>
</tr>
<tr>
<td>Figure 6.</td>
<td>Human skeletal muscle PDH – counts (DPM) measured over time of total PDH activity</td>
<td>73</td>
</tr>
<tr>
<td>Figure 7.</td>
<td>Rat skeletal muscle PDH activity – counts (DPM) measured over time with full PDH assay mixture and with and without essential cofactors</td>
<td>75</td>
</tr>
<tr>
<td>Figure 8.</td>
<td>Rat heart muscle PDH activity – counts (DPM) measured over time with full PDH assay mixture and with and without essential cofactors</td>
<td>76</td>
</tr>
<tr>
<td>Figure 9.</td>
<td>Effect of sciatic nerve stimulation on PDH activation in rat gastrocnemius skeletal muscle over various time periods with the same voltage</td>
<td>83</td>
</tr>
<tr>
<td>Figure 10.</td>
<td>The effect of sciatic nerve stimulation on PDH activation in rat gastrocnemius skeletal muscle over various time periods with varied voltages</td>
<td>84</td>
</tr>
<tr>
<td>Figure 11.</td>
<td>I. Training and immobilization of human skeletal muscle PDH activity</td>
<td>103</td>
</tr>
</tbody>
</table>
Figure 11. II. Immobilization and training of human skeletal muscle PDH activity. 103

Figure 12. III. Training, immobilization and exercise of human skeletal muscle PDH activity. 107

IV. Immobilization, training and exercise of human skeletal muscle PDH activity. 107

Figure 13. (a) PDH activity during unilateral exercise in human skeletal muscle. 112
(b) PDH activity during unilateral nerve stimulation of rat skeletal muscle. 112

Figure 14. Rat heart muscle PDH activity and pyruvate oxidation after treatment with epinephrine over various time periods. 114

Figure 15. Rat heart muscle PDH activity and cAMP concentration after treatment with epinephrine over time. 115

Figure 16. Rat heart muscle PDH activity and pyruvate oxidation after treatment with epinephrine and propranolol over time. 116

Figure 17. Rat heart muscle PDH activity and cAMP concentration after treatment with epinephrine and propranolol over time. 118

Figure 18. Rat heart muscle PDH activity and pyruvate oxidation after treatment with propranolol over time. 119

Figure 19. Rat heart muscle PDH activity and cAMP concentration after treatment with propranolol over time. 120

Figure 20. Rat heart muscle PDH activity and pyruvate oxidation after treatment with insulin over time. 121
Table 21. Rat heart muscle PDH, activity and cAMP concentration after treatment with insulin over time . . . . . . . . . 122

Figure 22. Rat heart muscle PDH, activity and pyruvate oxidation after pacing, by electrical stimulation over varying time periods . . . . . . . . . 123

Figure 23. Rat heart muscle PDH, activity and pyruvate oxidation after treatment with octanoic acid over time . . . . . 126

Figure 24. Rat heart muscle PDH, activity and cAMP concentration over time after treatment with octanoic acid . . . . . 127

Figure 25. Rat heart muscle PDH, activity and pyruvate oxidation with treatment of 200 /μM pyruvate over time . . . . . . . 128

Figure 26. Rat heart muscle PDH, activity and cAMP concentration after treatment with 200 /μM pyruvate over time . . . . . 129

Figure 27. Rat heart muscle PDH, activity and pyruvate oxidation after treatment with 1 mM pyruvate over time . . . . . 130

Figure 28. Rat heart muscle PDH, activity and cAMP concentration after treatment with 1 mM pyruvate over time . . . . . 131

Figure 29. Correlation between PDH activation and rate of pyruvate-14C oxidation in perfused rat heart . . . . . . . 132

Figure 30. Progressive cycle exercise in human skeletal muscle: The relationship between PDH activation and calculated muscle pyruvate oxidation . . . . . . . . 138

Figure 31. The effect of pyruvate concentration on PDH during rest and exercise in human skeletal muscle . . . . . . 142

Figure 32. Effect of pyruvate concentration and pyruvate oxidation in the perfused rat heart . . . . . . . . . . 142
ABBREVIATIONS

Biochemical and Chemical Compounds

ADP  - Adenosine-5'-diphosphate
ALD  - Alanine dehydrogenase
AMP  - Adenosine-5'-monophosphate
cAMP - Cyclic adenosine-3',5'-monophosphate
ATP  - Adenosine-5'-triphosphate
CK   - Creatine kinase
CoA  - Coenzyme A
CP   - Creatine phosphate
CPK  - Creatine phosphate kinase
Cr   - Creatine
DNA  - Deoxyribonucleic acid
F-1-P - Fructose-1-phosphate
F-1.6-P - Fructose-1,6-phosphate
F-6-P  - Fructose-6-phosphate
F-6-Pase - Fructose-6-phosphatase
FFA   - Free Fatty Acids
FA-CoA - Fatty Acid Coenzyme A
G-1-P  - Glucose-1-phosphate
G-6-P  - Glucose-6-phosphate
G-6-PD - Glucose-6-phosphate dehydrogenase
HK    - Hexokinase
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDH</td>
<td>Lactate dehydrogenase</td>
</tr>
<tr>
<td>NAD&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Nicotinamide-adenine dinucleotide, oxidized</td>
</tr>
<tr>
<td>NADH</td>
<td>Nicotinamide-adenine dinucleotide, reduced</td>
</tr>
<tr>
<td>NADP&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Nicotinamide-adenine dinucleotide phosphate, oxidized</td>
</tr>
<tr>
<td>PDH</td>
<td>Pyruvate dehydrogenase</td>
</tr>
<tr>
<td>PDH&lt;sub&gt;i&lt;/sub&gt;</td>
<td>Pyruvate dehydrogenase, inactive (phosphorylated)</td>
</tr>
<tr>
<td>PDH&lt;sub&gt;a&lt;/sub&gt;</td>
<td>Pyruvate dehydrogenase, active (dephosphorylated)</td>
</tr>
<tr>
<td>PDH&lt;sub&gt;t&lt;/sub&gt;</td>
<td>Pyruvate dehydrogenase, total: sum of (PDH&lt;sub&gt;a&lt;/sub&gt; + PDH&lt;sub&gt;i&lt;/sub&gt;)</td>
</tr>
<tr>
<td>PEP</td>
<td>Phosphoenol pyruvate</td>
</tr>
<tr>
<td>PFK</td>
<td>Phosphofructokinase</td>
</tr>
<tr>
<td>PK</td>
<td>Pyruvate kinase</td>
</tr>
<tr>
<td>TPP</td>
<td>Thiamine pyrophosphate</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetate</td>
</tr>
<tr>
<td>KRB</td>
<td>Krebs-Ringer bicarbonate</td>
</tr>
<tr>
<td>PCA</td>
<td>Perchloric acid</td>
</tr>
<tr>
<td>Tris</td>
<td>Tris(hydroxymethyl)aminomethane</td>
</tr>
</tbody>
</table>
SYMBOLS AND UNITS

dpm - Disintegrations per minute
r - Correlation coefficient
γ - Femtomoles
g - Grams
ht - Heart
i. units - International Units
Kpm - Kilopond meter
VO₂ max - Maximum oxygen consumption
MVIC - Maximum voluntary isometric contraction
x̄ - Mean value
Km - Michaelis constant
μl - Microliter
μg - Microgram
mmHg - Millimeter mercury
min. - Minute
ng - Nanogram
nmol - Nanomole
n - Number of observations
PCO₂ - Partial pressure carbon dioxide
PO₂ - Partial pressure oxygen
RQ - Respiratory exchange ratio (quotient)
sec. - Second
SEM - Standard error of the mean
$\text{VO}_2$ - Total oxygen consumption

Wet m. - Wet muscle weight
INTRODUCTION

The metabolism of glucose or glycogen to pyruvate and its subsequent oxidation to CO$_2$ is essential for normal muscle function. Its partial oxidation to pyruvate or lactate generates a limited but essential amount of energy (ATP) required for rapid muscle contraction. With sustained exercise it is necessary to increase and maintain ATP generation as the fundamental driving force for continued work. When glucose or glycogen serve as the major muscle energy source the regulation of pyruvate oxidation to CO$_2$ is perhaps the most important regulating step in muscle metabolism. Such metabolic regulation could be exerted at a number of different sites in the TCA cycle. On the basis of numerous studies$^{1-7}$ it has become generally acknowledged that the oxidation of pyruvate to acetyl CoA is a major, if not the primary regulatory step in the whole process of pyruvate oxidation to CO$_2$.

Before pyruvate can enter the tricarboxylic acid cycle (TCA), pyruvate must be oxidatively decarboxylated to acetyl CoA. The reaction responsible for this action is made up of several different enzymes known as the Pyruvate Dehydrogenase complex (PDH). In all tissues studied to date, PDH has been found to be a three enzyme complex which is
directly involved in oxidation of pyruvate in the inner mitochondria.\textsuperscript{1-5}

The three enzymes are as follows:

1. Pyruvate decarboxylase (EC 1.2.4.1)-Enz\textsubscript{1}.
   This enzyme is also known trivially as pyruvate dehydrogenase.*

2. Dihydrolipoate transacetylase (EC 2.3.1.12)-Enz\textsubscript{2}.

3. Dihydrolipoate dehydrogenase (EC 1.6.4.3)-Enz\textsubscript{3}.

The enzymes catalyze the following overall reaction in a sequential order.\textsuperscript{1,7-9}

\[
\text{Pyruvate} + \text{CoA} + \text{NAD}^+ \rightarrow \text{Acetyl Co-A} + \text{Co}_2^+ + \text{NADH} + \text{H}^+ 
\]

The various steps occur in the manner set out below:

(R1) Pyruvate + Thiamine pyrophosphate (TPP)-Enz\textsubscript{1} \rightarrow Co\textsubscript{2} + hydroyethyl-thiamine pyrophosphate - Enz\textsubscript{1}

(R2) Hydroxyethyl-TPP-Enz\textsubscript{1} + Lipoyl - Enz\textsubscript{2} \rightleftharpoons S-Acetyldihydrolipoyl - Enz\textsubscript{2} + TPP - Enz\textsubscript{1}

(R3) S-Acetyldihydrolipoyl - Enz\textsubscript{2} + CoA \rightarrow Acetyl CoA + Dihydrolipoyl - Enz\textsubscript{2}

* The use of pyruvate dehydrogenase here refers to the first reaction of the PDH complex, elsewhere in the thesis PDH is used to indicate the PDH complex.
(R4) Dihydrolipoyl - Enz₂ + FAD - Enz₃ $\xrightarrow{\text{Lipoyl}}$ - Enz₂ + FADH - Enz₃

(R5) FADH - Enz₃ + NAD⁺ $\xrightarrow{\text{NADH + H}^+ + \text{FAD - Enz₃}}$

The multi-enzyme complex forms a structural, functional and regulatory single unit of three enzymes and two other enzymes in higher organisms. The first reaction in the sequence is non-reversible while all the remaining reactions are reversible. (Figure 1)

The PDH multi-enzyme has been isolated from numerous organisms. The enzyme from pig heart muscle was the first to be isolated from the mammalian system. Since the 1950's the enzyme has been shown to exist in Escherichia coli, Azotobacter, Neurospora crassa, Streptococcus, yeast, potatoes, pigeon breast muscle, skin fibroblasts and many mammalian tissues.

1. MAMMALIAN PDH COMPLEX

The original work on the PDH complex (E. coli) postulated that there were 24 polypeptide chains of each enzyme in the even ratio of 1:1:1, for the three enzymes. However, upon closer analysis the ratio was found to be 1:1:0.5, where there were two polypeptide chains of Enz₁ and Enz₂ for each polypeptide chain of the flavoprotein
Enz. Since then, the exact ratio has not been resolved, nor has the molecular weight or polypeptide chain for each enzyme been definitely established.

Like the E. coli complex, the mammalian complex appears to vary between tissue types but the general consensus is that the molecular weight is about $10 \times 10^6$ and the complex may contain a nucleus of approximately 60 identical transacetylase units, (enzyme 2, Figure 1), each containing one moiety covalently bound to lipoic acid. When isolated, the pyruvate dehydrogenase (Enz₁, Figure 1), has a molecular weight (MW) of about 154,000 and consists of two subunits, one of 41,000 ($\alpha$-subunit) which binds TPP and Mg⁡⁺⁺ and decarboxylates pyruvate to give hydroxethyl-TPP. The other subunit of 36,000 ($\beta$-subunit), catalyzes the reduced acetylation of the oxidized lipoic acid on the transacetylase. It is postulated, therefore, that the $\alpha$-subunit of pyruvate dehydrogenase may catalyze reaction 1, while the $\beta$-subunit may be responsible for the catalyzing of reaction 2 (Figure 1).

Dihydrolipoate dehydrogenase (Enz₂) (Figure 1) has a MW of 110,000 and contains two similar or identical polypeptide chains, each containing one FAD molecule. The purified enzyme has 10 - 12 polypeptide chains of dihydrolipoate dehydrogenase. The transacetylase (Enz₂) functions both catalytically and in a structure forming way. It
forms the nucleus of the complex with the other two enzymes covalently bound on its surface (surrounded by Enz₁ and Enz₃ subunits).²⁵,⁴⁸

In addition to the three enzymes above, the mammalian enzyme complex contains a phosphatase and a kinase¹,⁷ which catalyzes the dephosphorylation (reactivation) and the phosphorylation (inactivation) of pyruvate dehydrogenase. This will be discussed in more detail later in the introduction.

2. ENZYME MECHANISMS

A. Pyruvate Dehydrogenase (Enz₁):

The decarboxylation of pyruvate is initiated by its binding to the 2-position of the thiazole ring of TPP (reaction 1).²³,²⁷-³¹

\[
\begin{array}{c}
\text{CH}_3\text{C-COOH} + \text{HC} - \text{S-C-R1} \rightarrow \text{Enz₁ - TPP} \rightarrow \text{COOH} - \text{HO-C} - \text{CH}_3 \\
\text{Pyruvate} \quad \text{Enz₁ - TPP} \quad \text{Enz₁ - TPP - pyruvate}
\end{array}
\]

After the binding of pyruvate, CO₂ is released from the enzyme complex of Enz₁ to form CO₂ and hydroxyethyl thiamine pyrophosphate ³¹-³⁵ (reaction 2).
B. Dihydrolipoate Transacetylase (Enz₂)

In mammals this enzyme catalyzes the transfer of the hydroxyethyl group from pyruvate dehydrogenase (Enz₁) to dihydrolipoate transacetylase (Enz₂)(reaction 3).\(^\text{11}\)
Lipoic acid contains 2-sulphur groups which are reduced with the oxidation of the hydroxyethyl group (reaction 3).\textsuperscript{13a,13b} The next stage of the reaction involves the formation of acetyl CoA (reaction 4).

\[
\begin{align*}
\text{CH}_2 & \quad \text{CH - Enz}_2 + \text{CoA} \rightleftharpoons \text{CH}_2 \\
\text{SH} & \quad \text{SH} \\
\text{S} & \quad \text{S} \\
\text{C} = \text{O} & \quad \text{C} = \text{O} \\
\text{CH}_3 & \quad \text{CH}_3 \\
\end{align*}
\]

(4) acetyl - Enz\textsubscript{2} \quad \text{Coenzyme A} \quad \text{Enz}_2 \text{ (reduced)} \quad \text{Acetyl CoA}

Unlike any part of the PDH complex this reaction is freely reversible.\textsuperscript{10,11} In fact the reversibility of this reaction is used as a test of purity in the separation of the various enzymes in this sequence. Acetyl CoA is a potent product inhibitor of Enz\textsubscript{2}; but its regulatory role remains to be established.\textsuperscript{8,36,80,84}

C. Dihydrolipoate Dehydrogenase (Enz\textsubscript{3})

The transfer of electrons from the reduced sulphur groups to NAD\textsuperscript{+} involves a complex series of steps. FAD is covalently linked to Enz\textsubscript{3} and is involved in the eventual transfer of electrons to NAD\textsuperscript{+}.\textsuperscript{37,38} The initial electron transfer is thought to occur as follows:
(5) \[
\begin{align*}
\text{CH}_2 & \quad \text{CH} - \text{Enz}_2 + \text{Enz}_3 - \text{FAD} \rightarrow \text{CH}_2 \quad \text{CH} - \text{Enz}_2 + \text{Enz}_3 - \text{FAD H}_2 \\
\text{SH} & \quad \text{SH} \quad \text{S-S} \\
\end{align*}
\]

Enz$_2$ - reduced \hspace{1cm} Enz$_3$-oxidized \hspace{1cm} Enz$_2$-oxidized \hspace{1cm} Enz$_3$-reduced

The reduced Enz$_3$ reacts with free NAD$^+$ to form NADH (reaction 6).

(6) \[
\begin{align*}
\text{Enz}_3 - \text{FAD H}_2 + \text{NAD}^+ & \rightarrow \text{Enz}_3 - \text{FAD} + \boxed{\text{NADH} + \text{H}^+} \\
\end{align*}
\]

The transfer of electrons from Enz$_3$ to NAD$^+$ involves sulfhydryl groups in addition to the FAD.\textsuperscript{8,13a,13b,39-41} The detailed sequence of electron transfer is poorly understood.

While dihydrolipoate dehydrogenase accepts electrons from lipoate bound to acetyl transferase, the lipoate dehydrogenase does not appear to contain much, if any, lipoate itself.\textsuperscript{2,8,37,38}

3. INTERCONVERSION AND REGULATION OF THE ENZYME

Recent work has shown the PDH complex to exist in two enzymatically interconvertible forms, one which is catalytically active and the other which is inactive.\textsuperscript{1,7,51,52} The two additional enzymes are a kinase which inactivates the PDH complex in the presence of ATP and low Mg$^{++}$ concentrations by phosphorylation, and a phosphatase which activates or dephosphorylates the complex in the presence of high Mg$^{++}$ and Ca$^{++}$ concentrations.\textsuperscript{66}
The PDH kinase is very tightly bound to dihydrodrioleate transacetylase (Enz₂).\textsuperscript{42} The PDH kinase has been separated from the transacetylase but has very low activity unless reconstituted with the transacetylase.\textsuperscript{25} The PDH kinase catalyzes the transfer of the terminal phosphate of ATP to at least two or three serine-hydroxyl groups per polypeptide chain of Enz₁.\textsuperscript{1,45} There are only about five PDH kinase molecules in the isolated complex and each of these molecules phosphorylates several Enz₁ chains.\textsuperscript{43,44} From the work of Davis et al.\textsuperscript{45} and others\textsuperscript{43,46,47} there appears to be good evidence that PDH is phosphorylated at different sites on the enzyme complex from different tissues. For example, the pig and bovine kidney and heart and pigeon breast muscle are phosphorylated on the same peptide subunit.\textsuperscript{25,43,46-48}

The PDH phosphatase, consisting of five polypeptide chains, is not as tightly bound as the PDH kinase and can be separated from the complex by ultra centrifugation.\textsuperscript{1,7,48} The site and mechanism of the binding of the PDH phosphatase is not yet clearly known. The PDH kinase and PDH phosphatase regulate the PDH complex activity by altering the activity of the first step in the complex (i.e. pyruvate decarboxylation). This step may be rate limiting for the whole PDH complex but it has never been confirmed experimentally.

The inactivation and reactivation by PDH kinase and phosphatase are under metabolic control and are modulated
by a number of effectors. Pyruvate, pyrophosphate and ADP inhibit the PDH kinase and hence activate the pyruvate dehydrogenase (Enz_1, Figure 1). 49-51 Other effectors like Mg" and Ca" inhibit the PDH kinase reaction and activate the PDH phosphatase reaction. 34, 52-55, 61 (Figure 2)

Pyruvate, the substrate for the enzyme, has been shown to protect PDH from phosphorylation and inactivation by the PDH kinase. 1, 7, 51, 56 The protection afforded the enzyme is eleven times more powerful for the heart than for kidney. 8, 51 These studies show that the protection by pyruvate is available to the heart, so that the oxidation by pyruvate cannot be blocked by cellular ATP generation. Kinetic studies have shown that there is a regulatory binding site for pyruvate that probably does not occupy the same position with the substrate binding site of Enz_1 or with the binding site of the ATP of the PDH kinase. 51, 57

The protective effect of pyruvate has been shown by Krebs 58, 59 to be important physiologically because the reducing equivalents necessary for gluconeogenesis have to be generated by the oxidation of pyruvate in the mitochondria when lactate is not the initial substrate. During these conditions, gluconeogenesis by way of oxaloacetate is only possible if some of the pyruvate is oxidized and, thus provides the NADH needed for that option. Pyruvate, therefore, prevents PDH inactivation by protecting the enzyme complex
Figure 2.

PDH Phosphatase

\[ \text{Pi} \]

PDH Inactive

PDH Kinase

PDH Active

ADP \rightarrow ATP

\[ \text{Co}_2 \]

\[ \text{NADH} \]

\[ \text{CoA} \]

\[ \text{NAD}^+ \]

\[ \text{Pyruvate} \]

\[ \text{Ca}^{++} \]

\[ \text{Mg}^{++} \]

Legend: The above scheme for PDH complex interconversion in mammalian tissue. A kinase phosphorylates and inactivates the enzyme while a phosphatase dephosphorylates and reactivates the enzyme. The properties that influence the activity are also summarized.
against the inactivation by the PDH kinase. Hughes and Burgett have shown that pyruvate inhibits phosphorylation of casein by the PDH kinase when separated from the enzyme complex, and feel that the PDH kinase may, therefore, bind and act at separate substrate and regulatory sites. Under certain conditions, especially when TPP is available, pyruvate concentrations lower than 100 μM, activate the PDH kinase while higher concentrations inhibit it. In the presence of TPP, pyruvate stimulates its own decarboxylation. This suggests that pyruvate or a decarboxylation product may be responsible for the inhibition of PDH kinase. Acetaldehyde and acetoin are some of the products available, but acetaldehyde has no effect, while acetoin activates the PDH kinase in low concentrations. The process does not occur if TPP is not available or if pyrophosphate is substituted. The reasons for the activation of the PDH kinase by acetoin formed from pyruvate with TPP, is not yet resolved.

Some carboxylic acids can also inhibit the PDH kinase while propionic acid appears to have a similar potency as pyruvate. Halogenated carboxylic acid such as dichloroacetate also inhibit the PDH kinase either in the presence or absence of TPP, but when compared to pyruvate and propionic acid, dichloroacetate is less effective. Therefore, the halogenated carboxylic acids can bind to PDH, do not get metabolized, and thus can activate the PDH complex.
It is suggested that the halogenated carboxylic acids activate PDH by stimulating the active or dephosphorylated form. It appears that the halogenated carboxylic acids activate PDH by inhibiting the PDH kinase reaction in some way, allowing the PDH phosphatase to dephosphorylate and, therefore, causing the conversion to the active PDH form.

Work from Reed’s and Wieland’s laboratories has shown that Mg$^{++}$ is required for PDH phosphatase activity. In the presence of EDTA, however, the enzyme was completely inactivated. These studies prompted Denton et al. and Pettit et al. to explore the effects of calcium ions on PDH activity in various tissues. The effect was to lower the $K_m$ of the phosphatase for its substrate PDH phosphate from about $30\mu M$ in the absence of Ca$^{++}$ to about $1.6\mu M$ with a calcium concentration of $10\mu M$. There also seems to be a reduction of the $K_m$ for Mg$^{++}$ if Ca$^{++}$ is available. Hayakawa and Hucho et al. have observed that the divalent metal Mn$^{++}$ may replace Mg$^{++}$, and Denton et al. further showed that some other divalent metals such as Sr$^{++}$ and La$^{++}$ could also mimic the effect of Ca$^{++}$ while Ba$^{++}$, Cu$^{++}$ and Fe$^{++}$ had no effects. Two other metals, Ni$^{++}$ and Zn$^{++}$, inhibited the effect of Ca$^{++}$ also. Siess and Wieland with their work, carried out at the same time, showed that fluoride could also inhibit the enzyme.
The adenine nucleotides may play a regulating role by the activation and inactivation of PDH by affecting the PDH kinase activity. ATP is an essential substrate for the PDH kinase, ADP is a weak PDH kinase inhibitor, while AMP, cyclic AMP and other nucleotides appear to have little influence on the regulation using purified, and partially purified mitochondria.\textsuperscript{1,15,49,52,65,69-74,168} As Hucho\textsuperscript{51} has pointed out the \( K_m \) of ATP for PDH kinase is low, so that the cell ATP concentration always saturates the PDH kinase. ADP and AMP, because of their weak inhibitory effects, are probably ineffective as regulators for the PDH kinase. The PDH phosphatase is not influenced by the nucleotides. Consequently, it has been difficult to determine how the interconversion of PDH changes according to the demands of the cell. It has also been difficult to show how the PDH enzyme complex activity is regulated by the nucleotides.\textsuperscript{9,67} It seems that the studies on the PDH kinase at least show that the regulation of the enzyme is very complex. There is some evidence, in heart, that the ATP:ADP ratio may exert an effect on the PDH activity.\textsuperscript{68-74} This will be discussed later.

Regulation by glycolytic intermediates in mammalian tissue PDH complex is subject to product inhibition by numerous metabolites.\textsuperscript{68-77} However, most of the studies with the intermediates have been conducted on the stimulation
of PDH in E. coli rather than in mammalian tissue. Such intermediates as fructose-diphosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate, phosphoenol pyruvate, dihydroxyacetone phosphate and glucose-6-phosphate stimulate the first step of the PDH complex (Enz₁). Very recently Ngo and Bardeau⁹⁰ reported that they were unable to observe any effects of brain PDH by the glycolytic intermediates. In addition to the activation of glycolytic products, product inhibition by NADH on Enz₃ in E. coli, and other tissues of the mammalian organs has been described.⁹,⁵¹,⁷₀,⁷₃-⁷₅,⁹₀ Acetyl CoA also inhibits PDH activity in all tissues tested to date. In contrast to E. coli a change in the free NADH:NAD⁺ ratio in mammalian tissue is more important in cellular metabolic regulation than the acetyl CoA:CoA ratio.⁷₄,⁷₅,⁸₁-⁸₃,⁸₅,⁸₆ The TCA cycle intermediates inhibit pyruvate oxidation in mammalian tissues with citrate influencing, as an example, the interconversion of the inactive to the active PDH.⁷₈,⁷⁹ (see p. 23 for further discussion).

4. Differences Between Organs in the Regulation of Mammalian Pyruvate Dehydrogenase

A. Brain: The brain PDH complex has been shown to be interconvertible by the phosphorylation and dephosphorylation process.⁶³ From data available so far it appears
that brain PDH activity can be regulated by different factors when compared with other organs. For example, when compared with kidney, heart, liver and adipose tissue, the brain PDH activity decreases far less during times of starvation. The heart, kidney and adipose tissue PDH are drastically reduced to between 15-20% of the PDH during starvation, whereas in the brain the PDH is never reduced by more than 50% of the PDH. \textsuperscript{1,7,87,88} This suggests that the rat brain has the ability to maintain a constant metabolic environment which is reflected as a minimal change in the PDH:PDH ratio.

There is some controversy whether acetyl CoA inhibits the PDH activity in the brain. Siess et al. \textsuperscript{86} have shown in rat brain that acetyl CoA was inhibitory, but Blass and Lewis \textsuperscript{89} reported that in ox brain it was not. Following up on the controversy, Wieland et al. \textsuperscript{88} and very recently Ngo and Bardeau \textsuperscript{90} have shown that under their experimental conditions, acetyl CoA inhibits PDH activity which is consistent with the results reported in most of the other tissues tested to date. \textsuperscript{74,75,86,91,94}

Jope and Blass \textsuperscript{92,93} have recently reported that in isolated rat brain mitochondria Mg\textsuperscript{++} and Ca\textsuperscript{++} when added to the medium do not activate the enzyme complex. In contrast, using liver mitochondria they showed an activation, under the same conditions, to be more than threefold. However,
Booth and Clark\textsuperscript{95} found that Mg\textsuperscript{++} and Ca\textsuperscript{++} were needed for maximal brain PDH activation. What is agreed upon is that the PDH\textsubscript{a} activity in brain is quite high. It appears to be about 70\% of the PDH\textsubscript{t} in mature fed rats which is somewhat higher than in most other tissues measured to date.\textsuperscript{9,87} Wilbur and Prote\textsuperscript{96} have shown that in immature rats, PDH\textsubscript{a} in brain is low but increases quickly during the first month of life. Other research has described that the PDH\textsubscript{a} varies with many different manipulations such as ischemia, insulin, starvation and the change in the energy charge.\textsuperscript{93,97} It seems in the above cases reported, that the proportion of the PDH\textsubscript{a} in brain changes rather than the PDH\textsubscript{t}. However, when mice have been exposed to ether, morphine, ethanol or diazepam the PDH\textsubscript{a} does not change, but those treatments do change pyruvate oxidation in the brain in vivo. Therefore, it can be concluded that treatments which alter pyruvate oxidation in brain tissue do not necessarily alter the PDH\textsubscript{a}:PDH\textsubscript{t} ratio.\textsuperscript{93}

B. Adipose Tissue: This tissue has been comprehensively studied in many laboratories.\textsuperscript{98-115} The activation of PDH in fat pads exposed to insulin has shown increases of approximately 2-3 fold when incubated with glucose or fructose. The response is very variable and may be due to high Ca\textsuperscript{++} concentrations found in the mitochondria of fat cells.\textsuperscript{116} As with brain PDH, the fat-pad PDH\textsubscript{t} activity is
not changed under most circumstances, however, the PDH activity can be. This has been confirmed when Mg$^{++}$ and Ca$^{++}$ are incubated with PDH phosphatase and the activation and inhibition of lipolysis are lost.\cite{103,106,107,116} The mechanism by which insulin activates PDH has not been elucidated. The known effects of insulin, like accelerated glucose uptake and inhibition of lipolysis, are perhaps secondary to other effects because accelerated glucose uptake has been observed in tissue incubated with fructose.\cite{117,118} The glucose uptake is not altered by insulin.\cite{105,108} Denton\cite{9} and others\cite{26,87,98,101,103,108,111,112} have found that many lipolytic agents such as epinephrine and dibutyryl cAMP increase PDH activity. However, when epinephrine and dibutyryl cAMP are added with insulin these agents stop the effect of insulin on PDH activity. Denton\cite{102,104,110,122} found no simple correlation between changes in rates of lipolysis and fatty acid synthesis, and changes in PDH activity. In the presence of nicotinic acid PDH activation was unaffected. The conclusions of Denton et al.\cite{104,120} and Stansbie et al.\cite{114,115} is that there could be a link between the rate of lipolysis and PDH activity under certain conditions, but the insulin effects are probably not dependable solely on changes in the rate of lipolysis. Short-term effects of insulin in decreased cAMP concentration are observed only in the presence of epinephrine or other agents which increase cAMP concentrations. An example of
this is the decrease of glycogen phosphorylase activity produced by insulin in the presence of epinephrine. Changes such as this, which are associated with a decrease of the activity of protein kinase and a lowering of cAMP concentration, seem to show that the lowering of cAMP may play an integral part in insulin action. Other effects are also observed and include increases in glucose transport, glycogen synthetase and PDH activation. Under these experimental conditions, the protein kinase, adenylase cyclase activation and cAMP concentration were not changed, signifying that the insulin effects do not appear to be cAMP dependent. With PDH, insulin appears only to act by activating the enzyme by increasing the rate of dephosphorylation in this tissue. However, whether insulin only activates the PDH phosphatase has not been resolved. Denton et al., Severson et al., Kerbey et al., and Hughes and Denton have been actively investigating effects that insulin has upon the mitochondrial concentration of the effectors of the PDH phosphatase and PDH kinase (see p. 11 and p. 12). It is well known that the PDH enzyme complex is altered by a number of effectors. High pyruvate and ADP, both inhibitors of the PDH kinase and Ca++, which activates the PDH phosphatase and inhibits the PDH kinase, have all been found to increase the proportion of the PDH complex in the active form. However, no convincing evidence has been obtained that the insulin action is mediated by changes in
whole tissue ATP:ADP ratio, NADH, NADH, acetyl CoA, CoA or potassium concentration.\textsuperscript{110,111,120,123} Up to this point in time, no effects have been shown with mitochondrial concentrations of adenine nucleotides or pyruvate within intact cells because techniques are not available to measure them. However, the effect of insulin is evident during the preparation of mitochondria from fat-cells or fat pads\textsuperscript{122} when pyruvate is absent. During this time it is presumed that pyruvate is not present in the mitochondria and as Denton et al.\textsuperscript{119,121} state, the ATP concentration in mitochondria treated with and without insulin is the same. This, then appears to suggest that changes in adenine nucleotides and pyruvate are not important as mediators of the effect of insulin.

A fairly recent approach to measuring the rate of the PDH kinase reaction within intact mitochondria has been to follow the incorporation rate of \textsuperscript{32}P from \( \text{[\textsuperscript{32}P]} \) \( P_i \) into PDH phosphate.\textsuperscript{34,51,121} From such experiments it has been found that the specific radioactivity of ATP in fat-pad mitochondria approaches that of the medium phosphate within seconds. The rate of the incorporation of \textsuperscript{32}P into PDH phosphate is taken as a measure of the rate of the PDH kinase reaction within intact mitochondria. The rate is greater in mitochondria from insulin treated fat-pads suggesting that the increase in the proportion of the active
form of the complex in the mitochondria was not caused solely by the inhibition of the PDH kinase.\textsuperscript{122}

Another possible mechanism by which insulin activates PDH has recently been suggested by Paetzke-Brunner et al.\textsuperscript{131} They suggested that the increase in PDH\textsubscript{a} in adipose tissue is a result of insulin reducing the acetyl CoA:CoA ratio in the mitochondria if acetyl CoA carboxylase is activated.

Fluoroacetate and insulin have similar effects on fat cell metabolism which has been interpreted to indicate a similar mechanism of action.\textsuperscript{9,128,129} Schiller et al.\textsuperscript{130} and Brownsey et al.\textsuperscript{128} have shown that both agents accelerate glucose transport, increase lipogenesis, and activate PDH but both decrease lipolysis and lower the \textsuperscript{2}CAMP concentration. The major difference between insulin and fluoroacetate seems to be that fluoroacetate induces the inhibition of PDH kinase while insulin does not.

Denton and Halperin,\textsuperscript{120} Denton,\textsuperscript{119} Denton et al.,\textsuperscript{122} Coore et al.\textsuperscript{100,101} and Halestrap and Denton\textsuperscript{125} have shown parallel changes in PDH\textsubscript{a} and acetyl CoA carboxylase proportions when the fat pad is treated with insulin and epinephrine which may suggest that the regulatory mechanism could be clearly linked.\textsuperscript{119} Both enzymes are involved in lipogenesis and as with PDH, acetyl CoA carboxylase exists in an inactive and active form. As an example, changes in cytoplasmic concentrations of fatty acid coenzyme A (FA-CoA)
might be responsible for activity changes of both PDH and acetyl CoA carboxylase if FA-CoA concentrations do, in fact, regulate the concentration of an effector of the PDH complex. Various workers\textsuperscript{9,124-126} have suggested that a decreased cytoplasmic FA-CoA concentration may be responsible for a decrease in the mitochondrial ATP:ADP ratio and hence the activation of PDH; but a conclusive role of FA-CoA has not been resolved.

The changes in citrate concentration has also been suggested as a possible regulator of the respective PDH and acetyl CoA carboxylase enzymes. Taylor and Halperin\textsuperscript{79} and Schiller et al.\textsuperscript{130} have shown that citrate appears to decrease PDH activity by inhibition of PDH phosphatase, possibly by chelating Mg\textsuperscript{++} and Ca\textsuperscript{++}. Both Mg\textsuperscript{++} and Ca\textsuperscript{++} have been described as activators of the phosphatase.\textsuperscript{1,7} Volpe and Vagelos\textsuperscript{127} have found that citrate activates acetyl CoA carboxylase and is inhibited by FA-CoA, but the importance of the effector is difficult to explain because there is little correlation between rates of fatty acid synthesis and whole tissue concentrations of citrate.

In summary, it is well established that the interconversion of the PDH\textsubscript{a} and the PDH\textsubscript{i} forms of the PDH complex in adipose tissue is influenced by hormones. Insulin results in an increase of PDH\textsubscript{a}. However, there seems to be confusion as to the actions of agents such as epinephrine. Certain laboratories have reported that PDH\textsubscript{a} activity in
fat-pads is increased after treatment by lipolytic agents in the absence of insulin, 99, 108, 111, 113, 117, 118 while another laboratory has shown that PDH$_a$ is not influenced by epinephrine used by itself. 101 The same authors have also found that some lipolytic agents oppose the reported increases of PDH$_a$ when insulin is available. When isolated fat-cells were used with epinephrine alone large PDH$_a$ decreases have been shown. 100-103, 119, 125, 126, 225 Possibly one reason for the differences is that the buffer used is often very different between laboratories. 100-102, 119, 125, 126, 225 An example is that wide variations in pyruvate concentrations are used. Others use glucose or fructose which allows some re-esterification of FFA derived from TG. 132, 144, 148

C. Liver: A large number of studies have produced direct evidence that phosphorylation and dephosphorylation observed originally by Linn et al. 147 in Reed's laboratory occurs in the liver of various different animals such as rats, 67, 86, 92, 113-137, 145, 146 mice, 138 guinea pigs, 139, 140 pigs 141 and developing immature rats. 142 Crude extracts from freshly prepared rat liver mitochondria and freeze-clamped samples of whole rat liver yields different activity concentrations but almost identical ratios of PDH$_a$:PDH$_t$. 135 This is similar to other tissues such as skeletal muscle where the proportions are almost identical but the absolute activities may be different. (see p. 112)
In livers from normal fed rats, the PDH\textsubscript{a} form accounts for only about 20\% of the PDH\textsubscript{t} activity.\textsuperscript{144,145} This is different from other tissues in the fed state such as heart muscle, kidney, brain and adipose tissue where the PDH\textsubscript{a} is at least 50\% of the PDH\textsubscript{t} activity.\textsuperscript{86,87}

During starvation there is a marked decrease in PDH\textsubscript{a} activity in the kidney and other tissues to approximately one sixth of the PDH\textsubscript{t}.\textsuperscript{87,107,132,144} In liver, starvation decreases the PDH\textsubscript{a} to about 10\% of the PDH\textsubscript{t} activity.\textsuperscript{145} This indicates that under normal fed conditions oxidative decarboxylation of pyruvate \textit{in vivo} occurs at a much lower rate in liver than in many other tissues. The feeding with glucose appears to cause similar PDH reactivation in the liver, heart and kidney.\textsuperscript{145}

In general, metabolic states associated with decreased plasma FFA concentrations result in an increase of PDH\textsubscript{a} activity whereas a rise in plasma fatty acids is associated with a lowering of PDH\textsubscript{a} activity. This, in turn, leads to an increase or decrease of mitochondrial ATP:ADP ratios which suggests that the mitochondrial energy state may be an important control of PDH\textsubscript{a}. However, other studies with adenine nucleotides appear to show that the ATP:ADP ratio remains essentially unchanged and possibly, therefore, does not effect the active or inactive PDH concentrations.\textsuperscript{79,147}
It has been observed also that the addition of octanoate causes a large 4-fold decrease in PDH\textsubscript{a} activity, without a change in the ATP:ADP ratio, indicating that the inactivation of PDH with this fatty acid is not due to changes of the ATP:ADP ratio.\textsuperscript{70,72,140,147,149-151} If octanoate is added to mitochondria oxidizing pyruvate, it does not change the ATP:ADP ratio.\textsuperscript{9,67,152} Pyruvate abolishes the effect of octanoate and shifts the PDH complex into a more active form.\textsuperscript{67,152} Wieland\textsuperscript{88} and others\textsuperscript{51,135} have shown earlier that incubation with 2.0 mM pyruvate converts PDH to over 80\% of its total activity. This activation appears to be similar to heart tissue. (see p. 28)

Pyruvate stimulation of PDH\textsubscript{a} kinase probably is not a major regulatory feature for the enzyme regulation in vivo. However, it does appear that, after decarboxylation of pyruvate, the acetylation of the lipoyl moiety reacts more slowly than the subsequent steps of the PDH reaction.\textsuperscript{154} The fraction of the lipoyl moieties in the acetylated form tend to reflect the acetyl CoA:CoA ratio and NADH:NAD\textsuperscript{+} ratio. Nevertheless, stimulation by pyruvate affords an important approach for detecting the stimulation of PDH\textsubscript{a} kinase activity. From the recent work of Cate and Roche\textsuperscript{154} pyruvate is shown to either stimulate or inhibit PDH\textsubscript{a} kinase activity. Both acetyl CoA and low pyruvate concentrations stimulate PDH\textsubscript{a} kinase to approximately the same level, while
the combination of pyruvate and acetyl CoA does not cause further stimulation. NADH also has been shown to induce inactivation of PDH in liver.72,140,152-154 This PDH kinase activity increase appears to be modulated by the reduction of the lipoyl moiety bound to the dihydrolipoyl transacetylase component and interaction of the dihydrolipoate at a site that activates PDH kinase activity. Significantly higher levels of PDH kinase activity are achieved with acetyl CoA or pyruvate than with NADH or dihydrolipoamide. The results of these studies suggest that both acetyl CoA and pyruvate stimulate PDH kinase activity by different mechanisms. Cate and Roche154 suggest that a common mechanism, such as stimulation of PDH kinase activity resulting from the release of inhibition by the oxidized form of the lipoyl moiety,73 seems unlikely. According to Cate and Roche, lipoic acid mediates the stimulation of PDH kinase activity, suggesting both the acetylated form of the lipoyl moiety is more effective than the reduced form in stimulating PDH kinase activity.141,154,155 Further experimentation seems to be required before the mechanisms are confirmed.

Very low NADH:NAD⁺ and acetyl CoA:CoA ratios reduce the activity in liver, as well as kidney and heart of the PDH activity by enhancing PDH kinase activity, while higher ratios are required for product inhibition of the overall PDH reaction.1,53,67,140,141,150,154,155
Insulin loading in liver produces marked activation of PDH$_a$ but when FFA was infused the increase in PDH$_a$ was abolished. In more recent work by Topping et al. Wieland's earlier work was confirmed, but showed in addition, that insulin modified in some way the effects of FFA on PDH$_a$. The effects appear to be mediated by changes in adenine nucleotides and their ratios. The ability of insulin to increase PDH activity may be due to an anti-lipolytic effect of the insulin. This may decrease the intracellular FFA available and the amount of FFA required for the reaction. Calcium ions also effect PDH interconversion and resemble the observed effects that occur in various other tissues. Calcium and magnesium have both been shown to be essential cofactors in liver and without their addition to the reaction medium very little activity occurs.

In summary, the interconversion of PDH in liver is regulated by adenine nucleotides, pyruvate, divalent cations, free fatty acids (FFA) and by modulation by the oxidation-reduction state of the mitochondrial ratios of NADH:NAD$^+$ and by acetyl CoA:CoA ratios. The liver PDH$_a$ activity in normal fed animals is much lower than in any other tissues.

D. Heart: The activity of the heart PDH complex, originally isolated from mitochondria by Linn et al., is regulated by phosphorylation and dephosphorylation. The site of the regulation is the pyruvate dehydrogenase
component of the multienzyme complex. Phosphorylation and concomitant inactivation of the three site (PDH) reaction is catalyzed by an ATP-specific kinase, first isolated in beef kidney mitochondria (a PDH kinase).\textsuperscript{1,7} The dephosphorylation and concomitant reactivation is catalyzed by a phosphatase (a PDH phosphatase). Beside the pyruvate dehydrogenase component, the PDH phosphatase has been shown to have been isolated from the dihydrolipoate transacetylase and dihydrolipoate dehydrogenase enzymes of the PDH complex and the three are functionally interchangeable. The PDH kinase has also been isolated from the three site sequence reaction and is active at low levels of Mg\textsuperscript{++}. The PDH phosphatase requires Mg\textsuperscript{++} at a concentration of approximately 10 mM and up to 10 mM of Ca\textsuperscript{++} for maximal activity.\textsuperscript{5,62} However, the Ca\textsuperscript{++} seems not to be as essential in the heart as it is in other tissues.\textsuperscript{79} There is recent evidence that the PDH phosphatase and PDH kinase components of the reaction are cyclic in their regulations. The PDH kinase has also been shown to be bound to the transacetylase component of the enzyme, while the two other enzymes of the PDH complex are also bound to the transacetylase.\textsuperscript{6,7} It has not as yet been conclusively shown that the PDH phosphatase is bound to the transacetylase in the heart although it has been shown that the transacetylase facilitates dephosphorylation of phosphorylated pyruvate dehydrogenase by the PDH phosphatase.\textsuperscript{7}
The PDH kinase in the heart is inhibited by pyruvate and ADP, especially if $K^+$ or $NH_4^+$ ions are present.\textsuperscript{51,52} Pyruvate protects the heart PDH complex against inactivation by ATP.\textsuperscript{51} Pyruvate has been shown by Hucho et al.\textsuperscript{51} and others\textsuperscript{9,53} to decrease the inactivation of PDH kinase at low concentrations. Heart PDH in mitochondria appears to be activated by larger concentrations of pyruvate. Pyruvate increases the PDH\textsubscript{a} proportion of the enzyme by inhibiting the PDH kinase activity.\textsuperscript{9,53,87} The inhibitory effect of pyruvate is more pronounced in the heart than in the kidney and other tissues such as brain and liver. According to Denton et al.\textsuperscript{9} fatty acids, ketone bodies and diabetes may interfere with the inhibitory effect of pyruvate on the PDH kinase resulting in phosphorylation and PDH inactivation. Pyruvate evidently produces less activation of PDH in mitochondria from alloxan-treated diabetic rats.\textsuperscript{9,162} It does seem likely that up to 75\% of the inhibition of pyruvate oxidation by fatty acids and ketone bodies is due to phosphorylation and the rest to end product inhibition. This probably occurs by the increased ratios of NADH:NAD\textsuperscript{+} and acetyl CoA:CoA facilitating phosphorylation and thus inactivation. No direct evidence supporting this is available.\textsuperscript{9,158,159,179}

Numerous effectors have been implicated in the regulation of the PDH kinase and PDH phosphatase, including changes in ATP:ADP, acetyl CoA:CoA and NADH:NAD\textsuperscript{+} ratios.
When fatty acids (octanoate, butyrate, palmitate, oleate and linoleate) are infused into the heart it has been shown that PDH is inhibited and thus inactivated, \(^{87,88} 107,144,161,163,179\) while the oxidation of pyruvate is also substantially inhibited. \(^{151,160,161,165-167,171}\) These conditions lead to an increase of CoA concentration and a large decrease in the acetyl CoA concentration. \(^{74,75,94,168}\) Recently, the PDH kinase has been shown to be activated by decreases in ratios of NADH:NAD\(^+\) and acetyl CoA:CoA. \(^{70,71,73,181-184}\) The implications of the interconversion of PDH have been explained by the changes in the ratios of mitochondrial NADH:NAD\(^+\) and acetyl CoA:CoA ratios in heart mitochondria of various different animals. \(^{72,163,169}\) The effect of the palmitoylcarnitine oxidation on PDH\(_a\) activity has also been implicated in similar ratio changes. \(^{151,169}\) From all the above studies it seems quite apparent that the effect of fatty acids and ketone bodies on pyruvate metabolism by the heart tissue is mediated by changes in NADH:NAD\(^+\) and acetyl CoA:CoA ratios and the decrease of PDH\(_a\) activity. Thus, the increased acetyl CoA:CoA ratio observed with FFA, could explain why FFA inhibited PDH\(_a\) activity. In addition, there probably is also direct feedback inhibition of the PDH\(_a\) by end products such as NADH and acetyl CoA. There is some evidence that small increases in the ATP:ADP ratio do not suffice to explain the changes in PDH\(_a\) activity in the
presence of palmitoylcarnitine and rotenone. It is fairly obvious that there must be other mechanisms leading to the PDH kinase activation. Portenhauser and Wieland\textsuperscript{164,181} appear to show that large NADH:NAD\textsuperscript{+} ratio increases in rotenone inhibited mitochondria with palmitoylcarnitine, and small increases of the ATP:ADP ratio, may modify the PDH complex sufficiently to cause some change in the PDH activity. When the heart mitochondria are incubated without substrates, the ATP:ADP ratio decreases up to a third and consequently the PDH\textsubscript{a} increases considerably.\textsuperscript{180-184}

Dichloroacetate was shown by Lorini and Ciman\textsuperscript{174} to elevate the R.Q. and lower the blood glucose concentration in alloxan-diabetic rats. Later studies in the early 1970's demonstrated that sodium dichloroacetate also stimulated pyruvate and glucose oxidation in rat heart and diaphragm, especially when the carbohydrate oxidation was inhibited by diabetes or by fatty acids or ketone bodies.\textsuperscript{175-178} The studies also concluded that acetate, ketone bodies and palmitate oxidation were inhibited by dichloroacetate. Later, McAllister et al.\textsuperscript{178} and others\textsuperscript{55,158,179} demonstrated that the PDH\textsubscript{a} portion of the PDH complex increased considerably in heart, diaphragm muscle, psoas muscle, fat and kidney after treatment with dichloroacetate. This agent has also been involved with the lowering of tissue citrate concentrations especially when the heart was perfused...
with acetate, ketone bodies or fatty acids.\textsuperscript{178}
Dichloroacetate also increases tissue concentrations of
acetyl CoA, acetyl carnitine, glutamate and lowers malate,
aspartate and pyruvate concentrations if perfused with
glucose plus insulin.\textsuperscript{176,178}

It has been suggested that citrate fails to accumulate
when perfused with acetate or ketone bodies because of a
decrease in pyruvate and perhaps oxaloacetate. The reason
for the suggestion came from the studies which showed
dichloroacetate not to decrease tissue concentration when
perfused with pyruvate.\textsuperscript{178} Dichloroacetate lowered pyruvate
and lactate concentrations in plasma and increased glucose,
pyruvate and lactate concentrations in the heart. The
studies of McAllister et al.\textsuperscript{178} and Whitehouse et al.\textsuperscript{179}
suggest that dichloroacetate activates PDH\textsubscript{a} by increasing
the acetyl CoA concentration which in turn may inhibit the
PDH kinase.

The consensus of opinion at this time seems to show
that the effects of fatty acid oxidation on PDH\textsubscript{a} activity
are not seen either in the presence of very low ATP:ADP
ratios or in the presence of Ca\textsuperscript{++} at about 10^{-6} M. The
ATP:ADP ratio, physiologically probably changes minimally in
the heart\textsuperscript{170,171} but fluctuations of Ca\textsuperscript{++} concentrations
may influence the PDH activity considerably more.\textsuperscript{172}

Calcium activates the PDH phosphatase reaction and
can also inhibit the PDH kinase enzyme. Studies with EGTA
(ethylene-glycol-bis(amoethyl)-tetra-acetate) and Ca-EGTA buffers in the heart mitochondria of pigs suggest that the PDH phosphatase is activated by $\mu$M Ca$^{++}$ concentrations in the presence of Mg$^{++}$.50,61,172 In the heart it was found that Sr$^{++}$ can be substituted for Ca$^{++}$ to activate PDH. Randle et al.172 have also described that in the presence of EGTA the $K_m$ of the PDH phosphatase was lowered for its substrate PDH phosphate from 30 $\mu$M to 1.6 $\mu$M. It is interesting that the concentration dependence of the effect of Ca$^{++}$ is similar to skeletal muscle phosphorylase b kinase.173 In comparison, Ca$^{++}$ variations below $10^{-6}$ M cause little or no change in the oxygen uptake of mitochondria in rat heart so that an indirect effect of Ca$^{++}$ on PDH interconversion involving an energy demand of Ca$^{++}$ uptake and increased NADH:NAD$^+$ and ATP:ADP ratios become very unlikely.72,106 Hansförd and Cohen162 feel, however, that the possibility of such an indirect mechanism could be shown if Ca$^{++}$ concentrations above $10^{-6}$ M were used.

The site of calcium binding in the heart is unknown. Transacetylase has been suggested as the binding site because Ca$^{++}$ may induce conformational changes that inhibit the PDH kinase while facilitating the binding and activity of the PDH phosphatase.

Calcium in the heart appears to activate PDH phosphatase in a similar way to the Ca$^{++}$ in kidney and
adipose tissue, except lower (μM) amounts of Ca²⁺ are needed in the heart. Calcium also appears to reduce the Kₘ for Mg²⁺ in all tissues tested. In addition, the PDH kinase is inhibited by Ca²⁺ in the heart but it is not known to what extent this applies to adipose tissue PDH or kidney PDH.

5. General Background to Thesis

These experiments were prompted by the physiological role, PDH activation might play in the regulation of skeletal muscle oxidation of pyruvate, derived from muscle glycogen and blood glucose during exercise.

There was considerable evidence that muscle ATP generated aerobically during heavy exercise was largely derived from muscle glycogen breakdown, with only a small proportion coming from other sources such as amino acids or FFAs. Thus, the major metabolic end point for glycogenolysis in muscle is pyruvate, which may be metabolized to lactate, or decarboxylated to acetyl CoA catalyzed by PDH. As the muscle O₂ consumption and CO₂ production increases at least 10 fold during heavy aerobic exercise, it follows that the major sources of aerobic metabolism is pyruvate oxidation derived from glycogen/glucose.

Since the PDH reaction is the committed step in pyruvate oxidation and aerobic generation of ATP, it seemed likely that control of glycogen/glucose oxidation was
probably largely at PDH.

When this work was started there were few published reports on muscle PDH and these were in diaphragm muscle\textsuperscript{49,74} and pigeon breast muscle\textsuperscript{3,4,20,21} and only in mitochondria, so it was decided to pursue studies in human and animal skeletal muscle PDH during rest and exercise without isolating mitochondria.

The purpose of the study was to determine whether PDH activation or changes in other factors known to inhibit or stimulate PDH activity, changed in a way which would implicate PDH as the major control point in regulating the TCA cycle activity and oxidative phosphorylation in skeletal muscle with heavy aerobic exercise.

Beside the various studies carried out in the mammalian skeletal muscle under different conditions, other studies were pursued in the rat heart. As PDH is the primary reaction that determines the metabolic fate of pyruvate in the heart and as the interconversion of the active and inactive PDH is regulated by a large number of factors,\textsuperscript{1,7,42,43,50,51} it was decided to explore which events in the cell between the cellular signal and final molecular interconversion were possibly accountable for the interconversion of the inactive and active PDH.

There is a basic assumption that if a main regulatory enzyme exists in an inactive and active state, the interconversion of the two states of the enzyme is the
primary factor in controlling the flow of carbon through that enzyme reaction. As that had not been established for PDH in the heart, studies in the perfused rat heart were carried out to determine to what extent of the PDH activation was the primary factor controlling the heart pyruvate oxidation.

Since this study was begun, several publications have appeared using mammalian skeletal muscle to explore certain aspects of the regulation of the enzyme PDH. These authors have used mitochondria to measure the PDH activity and none of these reports have described PDH activities in human muscle biopsies during exercise and training.

Accounts by Ward et al. and Toews et al. of some of these experiments have appeared.
MATERIALS AND METHODS

1. Materials

A. Animals

Male Sprague-Dawley rats (Bio-Breeding Corporation, Ottawa, Ontario, Canada) 200-300 g were used in all the animal experiments. They had free access to food (standard Purina laboratory chow) and water until the day before the experiments. The specific dietary regime for a day prior to the experiments is outlined in the text.

B. Chemicals

All the enzymes, cofactors and metabolic intermediates used in the fluorometric analysis of tissue and perfusion fluids were obtained from C.F. Boehringer-Mannheim Corporation, Montreal, Quebec, Canada or from Sigma Chemical Company, St. Louis, Missouri, U.S.A. All enzymes were checked for contaminating activity and were used only when their purity was established. The other chemicals were of the highest quality available commercially. Insulin [zinc insulin crystals] was obtained from Connaught Laboratories Limited, Toronto, Ontario, Canada; Propranolol (Inderal) from Ayerst Laboratories Incorporated, New York, N.Y., U.S.A. and bovine serum albumin (Cohn fraction V) was obtained from Sigma Chemical Corporation. \(^{14}C\)-compounds
were obtained from New England Nuclear Corporation, Boston, Massachusetts, U.S.A. or Amersham-Searle Limited, Oakville, Ontario, Canada. Sodium Heparin (Hepalein) was obtained from Harris Laboratories, Brantford, Ontario, Canada; epinephrine hydrochloride from Parke-Davis and Company Limited, Toronto, Ontario, Canada and sodium pentobarbital (Somnotol) from MTC Pharmaceuticals, Hamilton, Ontario, Canada.

2. Methods

A. MUSCLE MODELS

I. Heart Perfusion

All the rats were fasted for 18 hours before the experiments. They were anaesthetized with ether and the abdomen was opened. Two hundred i. units of sodium heparin was injected into the inferior vena cava to prevent coagulation in the myocardial vessels before any manipulation of the heart. The chest was opened and the heart was removed and placed on ice within 10 seconds of opening the chest. The aorta was then cannulated and flushed with ice-cold perfusion medium before the heart was placed on the perfusion apparatus.

In all the experiments the arrested hearts (weighing between 1 and 1.5 g fresh wt.) were restarted by perfusion with Krebs-Ringer bicarbonate buffer (KRB) \(^{186,187}\) containing
0.5 g bovine serum albumin (Cohn fraction V)/100 ml buffer. The albumin was dialyzed as previously described. In most of the experiments 10 mM D-glucose and 200 μU/ml insulin was added to the buffer. In many of the experiments, substrates other than glucose and the hormone insulin were used, and these details are described in the appropriate legends.

After the aorta was cannulated the heart was placed in the perfusion chamber at 38°C and perfused at an aortic pressure of 80 mmHg at an average flow rate of 10 to 15 ml/g ht/min. The heart was pre-perfused for 10 min. before 0 time. The perfusion was done in a non-recirculating manner with identical conditions, both before and after 0 time. At 0 time the heart was switched to a recirculating perfusion system with a reservoir volume of 200 ml. The heart was not electrically stimulated (except as outlined in the legends) and the heart did not contract against a ventricular pressure (non-working model); the heart maintained a ventricular rate of 120-160 beats/min. If this beating rate was not achieved the heart was discarded.

After 0 time the outflow samples were collected every 5 or 10 min. up to 40 min. (unless otherwise stated in the appropriate legends). At 40 min. the heart was freeze-clamped with aluminum clamps pre-cooled in liquid nitrogen. The heart was stored in liquid N₂ until analyzed.
II  Rat Skeletal Muscle

Fasted male rats were anesthetized with an intraperitoneal injection of 4 mg/100 g body weight sodium pentobarbital.

During anesthesia, the skin covering both hind legs was peeled back, leaving the gastrocnemius-plantaris muscle group or the quadriceps-femoris muscle tissue exposed. Depending upon the experiment, the gastrocnemius or quadriceps muscle groups in each leg were carefully dissected free from other muscle groups ensuring that the blood vessels and nerves were left intact. The sciatic nerves or femoral nerves (whichever was used for the experiments as shown in the appropriate legends) were transected bilaterally with as little manipulation as possible. The exposed areas were bathed with normal saline, recovered with the skin, and the animal was placed in a holding area at a temperature of 30-35°C for approximately 15 min. before any stimulation was begun. The sciatic or femoral nerve was cut in order to provide a direct point of nerve stimulation to the muscle and to prevent any neural influence from the brain. Blood lactate, arterial pH, $P_{O_2}$ and $P_{CO_2}$ were monitored to ensure that the experiments were as physiological as possible. Nerve transection resulted in minimal muscle contraction. To ensure a steady state during the experiments the rats were placed in the holding area for 15 min. prior to the
start of the experiment. The side to be stimulated was selected randomly; the contralateral leg always served as the control. The details of electrical nerve stimulation are outlined in the appropriate legends. At the end of the experimental period the particular muscle group used was freeze-clamped in situ by the use of aluminum tongs pre-cooled in liquid nitrogen. The frozen muscle (approximately 300 mg) was rapidly dissected free from the leg and stored in liquid nitrogen until analyzed. The maximal time between muscle sampling and freezing was 2-3 sec. As shown previously by Edington, Ward and Saville, 1973, the deep-muscle freezing time, as monitored by a thermistor, was 0.5 sec. to 0°C and 4.9 sec. to -100°C. Only one muscle sample per side was obtained because the sampling technique did not allow for multiple muscle biopsies.

(a) Rat Training Stimulus

The training stimulus was by running on a motor driven treadmill (Quinton Instruments, Seattle, Washington, U.S.A.) adapted for simultaneous use by 12 animals by the addition of wooden boxes. The training was carried out once daily for 5 days a week over a period of 10 weeks. The aerobic training program was initially begun at a speed of 19 meters/min. at 0% grade for 15 min. Each week the work rate was increased by 1.0% grade. In the final 2 weeks of the training program, the rats were running at 19 meters/min. at 5% grade for 45 min. daily.
(b) Surgical Procedure

Rats were anaesthetized with ether and the dorsal area of the lower leg exposed. The gastrocnemius-plantaris muscle group was thus divided and the soleus muscle and gastrocnemius muscles were dissected out from the leg. Both muscles were frozen in situ by liquid N₂ cooled aluminum tongs. The separate muscle samples were stored in liquid nitrogen until analyzed.

III Human Skeletal Muscle

(a) Short Term Exercise - Maximum Voluntary Isometric Contraction (MVIC)

Normal healthy male subjects (age 20-36) were used for all experiments. Two days before each experiment, the subjects were tested on a Cybex II dynamometer (Lumex Isokinetic Systems Inc., N.Y., U.S.A.) in a sitting position as described by Edwards et al.¹⁹¹,¹⁹² to determine their maximal voluntary isometric contraction (MVIC) of their lateral quadriceps femoris muscle group.

The experimental isometric contraction was at 50% MVIC until exhaustion. The time to exhaustion at a constant power output was 65-73 sec. Fifty percent MVIC was selected as the work load because an increase above this level decreased the time to exhaustion dramatically.
The muscle biopsies were obtained from the lateral side of the thigh about 12-16 cm above the upper part of the patella. Two percent xylocaine epinephrine free (Astra Pharmaceuticals Company, Toronto, Ontario, Canada) was injected into the skin subcutaneous area and the fascia lata. A 4 mm incision was made in the skin and fascia lata. The needle biopsy was obtained using a 4 mm diameter needle as described by Bergstrom. After sampling, the muscle sample (40-80 mg) was frozen with the needle in liquid nitrogen. The time from sampling to freezing was 2-3 sec. The samples were stored in liquid nitrogen until analyzed.

In all human studies, each subject was informed about the nature of the procedures and the risks involved. Written consent was obtained and each subject was informed that they were free to leave the studies at any time. Each study was approved by the McMaster University Ethics Committee.

(b) Long Term Exercise - Progressive Work

Normal volunteers starved for 12-16 hr, exercised on a cycle ergometer (Monark-Crescent, A-B, Varberg, Sweden) starting at 100 Kpm/min. and increasing the work rate by 200 Kpm every 2 min. Thus, the maximum work rate was 1700 ± 200 Kpm/min. and the total duration of the exercise was 20 min. The subjects exercised until exhaustion.
Prior to the start of the exercise regime, an arterialized venous polyethylene catheter (#18 Angiocath) was inserted into a superficial vein of the hand for intermittent blood collections. The hand was placed in a temperature controlled air chamber and the temperature was maintained at 40-45°C. The venous Po2 under these conditions was 75-84 mm Hg. The O2 consumption, CO2 production and ventilation was continually monitored.\(^{194}\) Exercise was not permitted 24 hr prior to the experiments. Muscle biopsies (40-80 mg) were obtained at rest and at exhaustion and handled as outlined earlier (p. 44).

(c) **Short Term High Intensity Exercise**

*Intermittent Work*

Six normal subjects, fasted 12-16 hr were exercised on a cycle ergometer for 1 min., followed by rest for 3 min. This cycle of exercise was repeated until exhaustion. The calculated work load was 140% of their maximal O2 consumption (\(V_{O2}^{\text{max}}\)).\(^{194}\) The average time between the start of exercise and exhaustion was 10.1 ± 1.6 min. An arterialized venous catheter was inserted for blood sampling prior to the beginning of the experiment and kept patent by an infusion of heparin-free isotonic saline (Abbotts Laboratories, Illinois, U.S.A.) and muscle biopsies were taken at rest and at exhaustion and frozen as described previously (outlined on p. 44).
(d) **Short Term Maximal Exercise - Anaerobic Type Work**

Normal subjects were exercised at 100% \( \text{VO}_2 \text{ max} \) until exhaustion on a cycle ergometer. The \( \text{VO}_2 \text{ max} \) for each subject was determined on a cycle ergometer a week prior to the experiments.

Muscle biopsies were taken at rest and at exhaustion. The exercise time to exhaustion varied from 63 to 68 sec. The muscle biopsies were obtained as outlined earlier (p. 44).

(e) **Training Induced Adaptation of Human Skeletal Muscle**

(i) **STUDY 1**

**Heavy Resistance Weight Training and Immobilization With the Arm**

Nine healthy male subjects completed this study (age 19-22 years, wt 61-75 kg). The variation in body weight during the study was less than 2% in all subjects. None had performed any regular resistance or weight-training during their lifetime. The scheme for the study is outlined in Figure 3. Upper arm girth was measured by a spring-loaded constant tension tape. Measurements were made before, during and after each section of the programme. Maximal voluntary contractile strength for elbow extention was measured concentrically on a Cybex II dynamometer at 30° per sec.

The muscle biopsy technique for the triceps brachii was similar to the technique used for the vastus lateralis
muscle as described earlier on p. 44. The long head of the triceps brachii was anaesthetized locally with 2% xylocaine (epinephrine free) and a 4 mm diameter needle was inserted through a 4-5 mm incision to a depth of about 4 cm below the skin. A 20-40 mg muscle sample from the non-dominant arm was obtained and frozen within 2-3 sec. and stored in liquid N$_2$ until analyzed.

(a) Training Programme: The subjects were trained in the following manner. The elbow extensors were trained by performing a bench press on the Universal Gym (Universal Sales Company, Fresno, California, U.S.A.), elbow extension and pullovers on Nautilus apparatus (Nautical Sports/Medical Industries, De Land, Florida, U.S.A.), and vertical dips between parallel bars with a suspended weight. For each work period, resistances were chosen to make it impossible for the subject to continue beyond 10 repetitions, and a maximum of 5 sets was performed with 2 min. rest periods between.

(b) Immobilization: Each subject had their non-dominant arm immobilized in a fiberglass elbow cast (Lightcast II, Merck and Company, West Point, Pennsylvania, U.S.A.) from the shoulder to the hand including the thumb, at 120°. The subjects’ movement was not restricted except for the non-dominant limb. The subjects were assigned at random into 2 groups.
Study 1

Group 1: Exercise + Implantation (15 min) + Control
Group 2: Implantation + Control
Group 3: Implantation + Exercise (15 min)
Group 4: Implantation + Exercise (6 weeks) + Control

Study 2

Group 1: Exercise + Implantation (6 weeks) + Control
Group 2: Implantation + Control
Group 3: Implantation + Exercise (6 weeks) + Control
Group 4: Implantation + Exercise (15 min) + Control

Legend:
1. Group 1 - Muscle biopsies were taken pre- and post-implantation and after 15 minutes of exercise.
2. Group 2 - Muscle biopsies were taken pre- and post-implantation after 6 weeks of exercise.
3. Group 3 - Muscle biopsies were taken pre- and post-implantation after 15 minutes of exercise.
4. Group 4 - Muscle biopsies were taken pre- and post-implantation and after exercise.

*Post-training and after exercise.*
Group 1: Members of this group resistance weight trained 4 days weekly for 1 hr daily on alternate days for 5 months, then had their non-dominant arm immobilized for 5 weeks.

Group 2: In contrast, group 2 members had their non-dominant arm immobilized for 5 weeks first, before beginning their 5 months of resistance weight training as above.

All girth and strength measurements were recorded on each subject in both groups before and after training periods, before the arms were placed in casts and within 12 hr of removing the casts after immobilization.

The muscle biopsies were taken before the study began and within 12 hr after the casts were removed, but 4-6 days were allowed to elapse after the final training session before the post training biopsies were taken. This procedure was followed to avoid any acute effects that may have occurred from the training programme. The biopsies were stored in liquid N\textsubscript{2} until analyzed.

(ii) Study 2

Heavy Resistance Weight Training, Immobilization and Exercise With the Arm

Six male subjects completed the study (age 19-23 years, wt 68-73 kg). None had performed regular resistance or weight training before the study.
The scheme of the study is outlined in Figure 3. The protocol was almost identical to the one outlined on p. 48 (Figure 3) except that the muscle was also biopsied before and after 15 min. of arm ergometry, and the arm cast period was extended to 6 weeks.

(a) Exercise: The exercise was carried out on a Monark ergometer adapted for the use of arm ergometry for 15 min. The exercise was done at 500 ± 50 Kpm producing a heart rate of between 145-155 beats/min. which was estimated to be about 50% of their VO$_2$ max.$^{195}$ The arm ergometry exercise took place at the beginning of the study (control), after heavy resistance weight training for 5 months and after 6 weeks of immobilization. The subjects were randomly assigned to two, 3 member groups (groups 3 and 4).

Group 3.: Members of this group resistance weight trained 4 days weekly for 1 hr daily on alternate days for 5 months and immediately thereafter exercised by arm ergometry for 15 min. Their non-dominant arm was then immobilized in a cast for 6 weeks, the cast removed and exercised again by arm ergometry for 15 min.

Group 4.: In contrast to group 3, the reverse procedure was followed for group 4. The non-dominant arm was immobilized for 6 weeks, the cast removed and the arm exercised by arm ergometry. Immediately after the exercise,
the 5 month resistance weight training programme was begun and when finished, exercise by arm ergometry was carried out.

All girth and strength measurements were recorded as described previously on p. 46.

Muscle biopsies were obtained in the following way:
(a) Before the experimental portion of the study began and after 15 min. of arm ergometry exercise. (These served as controls).
(b) Within 12 hr after the 6 week old immobilizing casts were removed, and after 15 min. of arm ergometry exercise.
(c) After weight training for 5 months, and after the 15 min. of arm ergometry exercise.

B. ANALYTICAL AND PREPARATION TECHNIQUES

I. Handling and Storage of Tissues, Blood, and Perfusate Samples

All the tissue biopsies were immediately frozen and stored in liquid nitrogen until analyzed. Prior to the extraction, the human skeletal biopsies were dissected free of blood, tendon and fat at -20°C in a cold room or on a block of solid carbon dioxide. The rat heart samples were dissected free of all non-ventricular material. The rat skeletal muscle was treated in a similar manner. The heart
perfusate samples and plasma samples were stored at -20°C until analyzed.

When the muscle samples were analyzed for PDHₐ and PDHₜ, the muscle (human skeletal muscle, 20-40 mg; rat heart, 200-400 mg; rat skeletal muscle, 200-400 mg) was chipped into 20-40 mg pieces on solid CO₂ and homogenized in 30 (human skeletal muscle) or 4 volumes (rat skeletal muscle and heart) of an ice-cold buffer containing 10 mM potassium phosphate, 1.0 mM diethiothreitol (DTT), 1 mM Na-EDTA and 1 g/l of crystalline bovine serum albumin (BSA), pH 7.4 for 40 sec. using a Polytron RT10 homogenizer.

The homogenate obtained was used directly for the assay of PDHₐ and PDHₜ as outlined on p. 63. The PDH assays were completed within 24 hr of muscle sampling.

The muscle samples used to assay the concentration of metabolic intermediates were extracted with 30 (human skeletal muscle) and 4 volumes (rat skeletal muscle, heart, perfusate and plasma samples) of ice-cold 6% perchloric acid (PCA). Immediately after adding PCA, the mixture was homogenized for 4 x ½ sec. bursts with a Polytron RT10 homogenizer. After centrifugation at 0°C, the supernatant was neutralized with 1N KOH containing 50 mM triethanolamine to a final pH of 6.0-7.0. The metabolites in question were assayed within 4 hr of neutralization.
The muscle samples used for glycogen analyses, however, were usually treated differently after they were frozen. As the muscle tissue to be used was often very small (usually less than 20 mg), the sample was homogenized with a Polytron directly in a volume of 1 ml 0.1 M acetate buffer pH 4.75 (0.05 M acetic acid : 0.05 M sodium acetate) and used directly for the assay of glycogen as outlined on p. 60. If larger muscle samples were available, they were homogenized with a Polytron in 1N HCl at 0°C, boiled for 5 min. and analyzed immediately or stored at 5°C. All assay methods are outlined on p. 60.

II Fluorometric Analysis of Metabolites

(a) Tissue Metabolites

The methods used to determine the metabolite concentrations were based upon those of Bergmeyer 1963 and modified in this laboratory. Measurements were usually carried out on an Aminco Fluoro-Microphotometer (American Instrument Company, Silverspring, Maryland, U.S.A.) or an Eppendorf-Geratebau 1030 Photometer with an Eppendorf Recording Adapter 2134 (Hamburg, West Germany), but when the concentrations of the intermediate would be low, the measurements were made on a Farrand Ratio Fluorometer-2 (Farrand Optical Company Inc., New York, N.Y., U.S.A.).

The Excitation wavelength was 340 nm and the Emission wavelength was 460 nm.
(1) Adenosine Triphosphate (ATP) and Creatine Phosphate (CP)

The principle of these assays involved the reaction outlined below:

\[
\begin{align*}
(1) \quad & \text{glucose} + \text{ATP} \xrightarrow{\text{hexokinase}} \text{G-6-P} + \text{ADP} \\
(2) \quad & \text{G-6-P} + \text{NADP}^+ \xrightarrow{\text{dehydrogenase}} \text{6-phosphogluconolactone} + \text{NADPH} + \text{H}^+ \\
(3) \quad & \text{CP} + \text{ADP} \xrightarrow{\text{phosphokinase}} \text{creatinine} + \text{ATP}
\end{align*}
\]

The 2 ml reaction mixture contained:

- 25 mM Tris
- 0.5 M Hydrazine hydrate
- 5 mM D-Glucose
- 100 \( \mu \)M NADP\(^+\)
- 5 \( \mu \)M Mercaptoethanol
- 100 \( \mu \)M Na-EDTA
- 5 mM MgCl\(_2\) with a final pH 8.5

The ATP concentration was determined as follows:

Two ml of reaction mix containing an acidified-neutralized extract of muscle (equivalent of 2-10 mg of wet muscle), 10 \( \mu \)g of glucose-6-P dehydrogenase, and the change in baseline fluorescence with time was established. When the baseline was stable, 10 \( \mu \)g of hexokinase was added. This resulted in a rapid increase in fluorescence due to conversion of the ATP to ADP by hexokinase, which in turn,
generates equimolar quantities of glucose-6-P and NADPH via glucose-6-P dehydrogenase. The assay was considered accurate when standard quantities of ATP and NADPH produced the same increase in fluorescence.

A representative assay for ATP and CP is shown below:

At point A 2 ml of reaction mix with muscle extract was placed in the fluorometer (Eppendorf). At point B, 10 μg of glucose-6-P dehydrogenase (G-6-PdeH) was added. The small but rapid increase was due to muscle glucose-6-
phosphate content. At point C 10 μg of hexokinase (HK) was added. The rapid increase in fluorescence was due to conversion of ATP to ADP catalyzed by HK. The end point measurement was formation of fluorescent NADPH by G-6-P dehydrogenase. The fluorescence change shown as Point D represents the quantity of ATP present in the sample. At point E 10 μg of creatine phosphokinase was added. The rapid increase in fluorescence was due to the following sequence of reactions:

\[ \text{CP} \rightarrow \text{Creatine} \quad \text{Glucose} \rightarrow \text{G-6-P} \rightarrow \text{G-P-G} \]

(ii) **Pyruvate, Adenosine Diphosphate (ADP) and Creatine (C)**

The principle of these assays is shown in the reaction below:

(1) \[ \text{pyruvate} + \text{NADH} + \text{H}^+ \xrightarrow{\text{LDH}} \text{lactate} + \text{NAD}^+ \]

(2) \[ \text{PEP} + \text{ADP} \xrightarrow{\text{PK}} \text{pyruvate} + \text{ATP} \]

(3) \[ \text{creatinine} + \text{ATP} \xrightarrow{\text{CK}} \text{CP} + \text{ADP} \]

The reaction mixture contained in tube (2 ml) the following:
25 mM Triethanolamine
5.0 mM KCl
5 mM MgCl₂
0.25 mM Phosphoenol pyruvate
20 μM NADH, final pH 7.4

Since reaction (1) and (2) are coupled by pyruvate that is formed in reaction (2), it was imperative to react all pyruvate already present in the reaction solution.

Two ml of reaction mix containing an acidified-neutralized extract of muscle (equivalent of 2-10 mg of wet muscle), and 10 μg of lactate dehydrogenase (LDH) was added to drive the reaction. The resulting decreased fluorescence was measured, this was the pyruvate formed (1) from NAD⁺. The assay was considered completed after a further 10 μg LDH was added to check if there was no further fluorescence. The second stage of the reaction was begun by the addition of 10 μg pyruvate kinase (PK) and after 30 min. the reaction was complete. The decrease of fluorescence was due to the conversion of ATP to ADP (2) by the PK. The fluorescence was checked by the addition of a further 4 μg PK.

A new baseline was then established when excess ATP (100 μM) was added to the assay mix. After baseline, 20 μg creatine kinase (CK) was added to produce reaction (3) which is the creatine. A further 20 μg CK was added to check fluorescence. Appropriate known standards were used for each section of the assay reaction. The decrease in
fluorescence was quantitated by comparison with the decrease in the fluorescence obtained with the known amounts of standard.

(iii) Lactate

The reaction is shown below:

\[
\text{LDH} \quad \text{lactate} + \text{NAD}^+ \rightarrow \text{pyruvate} + \text{NADH} + H^+
\]

The lactate was measured enzymatically utilizing a NADH:NAD\(^+\) coupled reaction which recorded the increase in fluorescence due to NADH formation.

The reaction ran to completion because pyruvate was removed by hydrazine. The reaction mixture (2 ml) contained:

- 25 mM Tris
- 0.5 M Hydrazine hydrate
- 200 μM NAD\(^+\)
- 5 μM Mercaptoethanol
- 100 μM Na-EDTA with a final pH of 8.5

Lactate dehydrogenase (10 μg) was added to 2 ml of incubation medium in the cuvette.

Varying amounts of muscle extracts were used to determine the lactate present. The assay system was standardized using known amounts of lactate and NADH. The assay was considered satisfactory if the lactate and NADH standards changed the fluorescence to the same extent. The execution of the assay was as outlined as on p. 55.
(iv) **Glucose**

Glucose was measured enzymatically by fluorometric techniques in the reaction set out below:

1. \[ \text{glucose} + \text{ATP} \xrightarrow{\text{hexokinase}} \text{G-6-P} + \text{ADP} \]

2. \[ \text{G-6-P} + \text{NADP}^+ \xrightarrow{\text{dehydrogenase}} 6\text{-phosphogluconolactone} + \text{NADPH} + \text{H}^+ \]

The reaction mixture contained the following:

- 25 mM Tris
- 0.5 M Hydrazine hydrate
- 1.0 mM ATP
- 5 μM Mercaptoethanol
- 100 μM Na₂EDTA
- 1.0 mM NADP⁺ with a final pH 8.5

The glucose concentration was determined by the following manner. Two ml of reaction mix containing 5-500 μl acidified-neutralized extract of muscle (equivalent of 2-10 mg of wet muscle), 10 μg of glucose-6-phosphate dehydrogenase (G-6-PD), and the change in baseline fluorescence with time was established. When baseline was established and the first reaction stable, 10 μg HK was added and the glucose formed, measured.
(v) **Glycogen**

The reaction is as follows:

1. \((\text{glucose})_n + (\text{H}_2\text{O})_{n-1} \xrightarrow{\text{amyloglucosidase}} n - \text{glucose}\)

2. \(\text{glucose} + \text{ATP} \xrightarrow{\text{hexokinase}} \text{G-6-P} + \text{ATP}\)

3. \(\text{G-6-P} + \text{NADP}^+ \xrightarrow{\text{dehydrogenase}} \text{6-phosphogluconate} + \text{NADPH} + \text{H}^+\)

Glycogen analysis was performed by enzymic hydrolysis with the enzyme amylo-\(\alpha\)-1,4-\(\alpha\)-1,6-glucosidase followed by enzymic assay of glucose as described by Passoneau and Lauderdale,\(^{197}\) Nahorski and Rogers\(^{198}\) and modified in this laboratory.

The reaction mixture contained:

- 50 mM Triethanolamine
- 1.0 mM ATP
- 1.0 mM NADP^+
- 5 mM MgCl\(_2\) with a final pH 7.8

The incubation mixture contained:

- 100 mM Acetate (50 mM acetic acid : 50 mM Na acetate) with a final pH 4.75

The skeletal muscle (50-100 mg wet muscle) was homogenized in the acetate buffer and to an aliquot of the
buffer which contained (2-10 mg wet muscle equivalent) 30 ng of amylo-glucoosidase in a volume of 5 \( \mu \)l was added to begin the reaction and the mixture incubated at room temperature for 1 hour. After incubation 200 mM Tris was added to each incubated aliquot.

A 25 \( \mu \)l sample of the incubation mixture was then added to the reaction mixture. Glucose-6-phosphate dehydrogenase (2 \( \mu \)g) is added directly to the reaction mixture or added to each aliquot separately. The resulting fluorescence was measured and 2 \( \mu \)g NAD was added to drive the reaction and the glucose formed from the enzymatic degradation of glycogen measured. The NADPH formed was also measured after 10 min. at room temperature. The glucose and G-6-phosphate from the NADPH was also measured and subtracted from the sample containing amylo-glucosidase.

The amylo-\( \alpha \)-1,4-\( \alpha \)-1,6-glucosidase liberates the glucose from glycogen by hydrolyzing \( \alpha -(1-6) \)-linkages as well as \( \alpha -(1-4) \)-linkages \( \text{(1)} \). Glucose (2) was converted to 6-phosphogluconate in one step by glucose-6-phosphate dehydrogenase and hexokinase. Appropriate standards of glycogen and glucose were used at each step.

(vi) Cyclic AMP

Muscle cyclic AMP was determined by a radioimmunoassay of Steiner et al., 1972. \( ^{246} \).
The assays were kindly performed by Dr. M. Rathbone of the Department of Neurosciences, McMaster University, Hamilton, Ontario, Canada.

(b) Blood Gases and Blood pH

Arterial blood Pco\textsubscript{2}, Po\textsubscript{2} and pH were determined on a Radiometer (Copenhagen) PH M72-MK2-Digital Acid-Base Analyzer and a BMS3-MK2-Blood Micro system.

(c) Plasma Glucose

Plasma glucose concentration was measured by enzymic fluorometric techniques in PCA and neutralized with potassium bicarbonate as described by Lowry and Passoneau, 1972\textsuperscript{199} and on p. 59 of the text.

(d) Plasma Lactate

Plasma lactate concentration was measured using enzymatic fluorometric methods in PCA extracts by the method of Toews\textit{ et al.}, 1970\textsuperscript{200}

III Preparation of Mitochondria

For preparation of mitochondria, fresh rat heart and skeletal muscle was removed under anaesthesia (p. 39) and the procedure was a modification described by Chappell and Hansford, 1972\textsuperscript{201} and Hansford, 1974\textsuperscript{202}. The tissue was
rinsed in ice-cold sucrose medium (0.25 M sucrose, 5 mM Tris-HCl and 2 mM ethylene-glycol-bis-(aminoethyl)-tetra-acetate (EGTA), pH 7.4). The tissue was then cut up with scissors in 5 ml sucrose medium and homogenized with a Polytron PT10 homogenizer for 3 x 10 sec. at one third the maximum speed at 0-2°C. The cell debris was precipitated by slow-speed centrifugation (600-650 g for 10 min.) The supernatant was then centrifuged at 10,000 g for 1 hr. The pellet was resuspended in sucrose medium and diluted to 20 mg of protein/ml. The yield was approximately 5-10 mg of mitochondrial protein/g muscle. All operations were carried out at 0-4°C.

Pyruvate dehydrogenase activity in unfractionated rat skeletal muscle was approximately 300 ± 16 nmol/g/min. In unfractionated rat heart muscle it was approximately 1240 ± 30 nmol/g/min. Mitochondrial PDH activity was 5-7% of the total muscle activity.

Mitochondrial protein was determined by the method of Lowry et al., 1951.

IV Pyruvate Dehydrogenase (PDH) Assay

The muscle samples used for the PDH assays were stored and extracted as outlined on p. 51.

Pyruvate dehydrogenase was assayed by a modification of the method described by Taylor et al. The assay mix
for PDH<sub>a</sub> contained 25 mM potassium phosphate, 2.5 mM Na-EDTA, 2.5 mM MgCl<sub>2</sub>, 0.5 mM CoA, 2.5 mM dithiothreitol (DTT), 30 mM NAD<sup>+</sup>, 1.5 mM thiamine pyrophosphate (TPP), 0.8 mM Na pyruvate, Na-pyruvate-1-<sup>14</sup>C (1.7 μC/ml) and 2 g/l crystalline bovine serum albumin, (pH 7.4). One quarter ml of the assay mix was added to a 10 ml Erlenmeyer flask cooled on ice in a cold room, with a disposable plastic center well (Kontes Glass, Vineland, N.J., U.S.A.) containing 0.2 ml of 10 N Hyamine hydroxide. The flasks were sealed with a rubber stopper containing the center well. The assay mixture was incubated at 37°C, and 0.2 ml of ice cold muscle homogenate was added 1 min. after incubation. The Na-pyruvate-1-<sup>14</sup>C was added just prior to addition of muscle homogenate to minimize nonspecific pyruvate-1-<sup>14</sup>C decarboxylation. The control incubation was identical except no muscle extract was present. The assay mixture was incubated for 2 min. after enzyme added and then stopped by adding 0.8 ml of a solution containing 0.08 M citric acid and 0.04 M N<sub>2</sub>PO<sub>4</sub>, pH 3.0 under closed conditions. All the <sup>14</sup>CO<sub>2</sub> was trapped in the Hyamine hydroxide center well after 60 min. The <sup>14</sup>CO<sub>2</sub> was determined in the center well using standard scintillation counting techniques. The counting efficiency was determined using the channels ratio method and/or by use of an external standard.
The PDH$_t$ activity was determined as described above except that the muscle extract was incubated for 6 min. in the buffer also containing 10 mM MgCl$_2$ and 10 mM CaCl$_2$. The Mg$^{++}$ and Ca$^{++}$ dephosphorylated the PDH$_t$ forming PDH$_a$ within the 6 min. incubation.

The lowest background counts were obtained when the Na-pyruvate-$1^{14}$C was used just prior to assay.

V The Method for Determining the Specific Activity of Pyruvate

This method was developed to measure the specific activity of pyruvate in muscle extracts.

The principle of the method is as follows:

Pyruvate behaves as an anion and alanine as a cation on a cation exchanger at pH 7.4. Pyruvate can be quantitatively converted to alanine by the following reaction:

\[
(1) \ \text{pyruvate} + \text{NADH} + \text{NH}_4^+ + \text{H}^+ \rightarrow \text{alanine} + \text{NAD}^+ + \text{dehydrogenase}
\]

In any muscle extract any added labelled pyruvate will be partially present as alanine because of the rapid interconversion of these two intermediates. In the initial acidified-neutralized extract all the cations, including alanine, were removed by passing the solution through a cation exchange resin (Dowex (50 x 12 - 100) -50 W, Sigma Chemical Company, Missouri, U.S.A.). The effluent from the
column contained all the anions, including pyruvate. The pyruvate was then converted to alanine with alanine dehydro-
genase and excess NADH, and repassed through a cation exchange resin. Since alanine dehydrogenase is specific for pyruvate, any $^{14}$C retained by the column will be derived from pyruvate-$1^{14}$C. The alanine is extracted from the cation exchange resin using 5N KOH and counted as $^{14}$C as outlined on p. 68. The validity of the ion exchange chromatography was checked using alanine-$1^{14}$C and Na-pyruvate.

Preparation of Sample

Frozen heart muscle was pulverized at -20°C into small pieces and homogenized with a Polytron as described on p. 51. After centrifugation at 4°C the supernatant was decanted, neutralized to pH 7.4 with 5N KOH and the sample recentrifuged. The supernatant was divided into 2 aliquots; one 2 ml aliquot was immediately freeze-dried and stored as powder at -20°C for future analysis of metabolites. The remaining was treated as outlined below:

Assay

(1) A 2 ml aliquot of muscle supernatant pH 7.4 was added directly to cuvette and placed in an Eppendorf 1030 photometer or a Farrand ratio-2-recording fluorometer.

(2) After a stabilization period for baseline fluorescence, 15 μM NADH was added to cuvette and converted
to NAD⁺, baseline readjusted; and 5 mM (NH₄)₂SO₄ was added and the baseline adjusted again.

(3) To the mix was added 5 μg alanine dehydrogenase to begin the reaction.

(4) When the reaction was completed another 5 μg alanine dehydrogenase was added to check whether the reaction was indeed completed.

(5) As a further check for the completion of reaction, a small amount of Na-pyruvate was added directly to cuvette. If the reaction was complete a further reaction would then take place with the pen travelling off scale.

(6) After the pyruvate to alanine reaction was completed, the complete assay mix was saved.

(7) The saved 2 ml mix was carefully passed through another cation exchange resin column and eluted with 2 ml 5N KOH and washed with 2 ml water. The alanine produced during the assay was trapped on the column and the pyruvate passed from the column. The effluent was neutralized to pH 7.4 with PCA, and the precipitate was centrifuged at 10,000 rpm to remove the potassium perchlorate, and the supernatant decanted directly into a scintillation vial. The resulting pellet was mixed and rinsed once with 0.5 ml water and centrifuged. The supernatant was combined with the first spin supernatant in the scintillation vial and immediately freeze-dried.
(8) Once freeze-dried, the vials were either stored, or 10 ml of scintillation mix was added directly to the vial. Before counting, it was desirable to add fumed silica 3-4 g/100 ml (Cab-O-Sil, grade 5 - Cabot Corporation, Boston, Mass., U.S.A.). A uniform mix and a slightly better counting efficiency resulted. The vials were counted by standard scintillation counting techniques as described on p. 69.

VI $^{14}$C Determinations

The scintillation fluid for counting $^{14}$C determinations was toluene:ethanol (9:1, v/v) containing POPP $^{[1,4$-bis-(5-phenyloxazol-2-yl)-benzene]}$ 50 mg/l, PPO (2,5-diphenyloxazole) 5 g/l napthalene 130 g/l and dioxane.

The radioactivity was determined at 4°C in a Beckman LS-230 liquid scintillation counter. Efficiency was determined by the channels ratio method.

VII $^{14}$CO$_2$ Production

$^{14}$CO$_2$ production was determined by collecting the effluent from the hearts in T-flasks under a layer of mineral oil in preweighed beakers. The effluent volume was determined gravitationally. A 4 ml aliquot was transferred to a 10 ml Erlenmeyer flask sealed with rubber stopper and disposable plastic center well containing 0.4 ml 10 N H$_2$amine hydroxide.
The aliquot was then acidified with 4 ml 0.5 M citric acid and incubated for 60 min. at 20°C. The liberated $^{14}\text{CO}_2$ absorbed into the Hyamine hydroxide was placed directly into a scintillation vial and counted in toluene-based scintillator as described above. The recovery of $^{14}\text{CO}_2$ in the center well from $^{14}\text{CO}_2\text{-HCO}_3^-$ in the mask was 97 ± 3%.

VIII Calculations and Statistical Analysis

Statistical analysis was evaluated by using the student's 't' test.
RESULTS

1. Development of PDH Assay Method

In the initial experiments, skeletal muscle mitochondria were isolated and prepared as described earlier on p. 62. The isolation technique resulted in only 5-10% recovery of the mitochondria. The effect of PDHα and PDHβ activation versus a function of incubation time is shown in Figure 4. It is apparent that the PDHα and PDHβ activity was linear with enzyme concentration to a mitochondrial concentration of 0.5 mg mitochondria protein/0.5 ml. In other experiments, (Figure 5), it was demonstrated that the rate of pyruvate oxidation by PDH was linear with time.

Because the recovery of mitochondria from muscle is unpredictable and low and because the human muscle biopsy samples are small, it was necessary to develop a PDH assay that could be reliably used in muscle homogenates obtained from a needle muscle biopsy. A variety of different techniques were used and the one described on p. 63 was found to be the most reproducible.

Using the muscle homogenate preparation of PDH, the activity was linear with muscle content and the PDH activity was linear with time (Figure 6).
**Figure 4:**

The effect of mitochondrial protein on PDH activity. Mitochondria from rat skeletal muscle was used for determining PDH. Enzyme activity was calculated before and after preincubation at 37°C with 10 mM Ca²⁺ and 10 mM Mg²⁺. The PDH activity was expressed in nanomoles pyruvate oxidized per mg of mitochondrial protein. Results are means ± S.E.M. and the number of observations for each point is as indicated at the end of the linear line.
Figure 5.
Relationship between initial velocity versus time and enzyme concentration of PDH. The activity of PDH was determined as in "Materials and Methods". PDH$_a$ and PDH$_t$ activity was measured over varying time periods. Mitochondria were prepared from rat skeletal muscle and were used for PDH assays. Samples for PDH$_t$ were incubated at 37°C. The $^{14}$CO$_2$ produced was calculated and the pyruvate oxidized, expressed as nmoles per mg of mitochondrial protein. There were 10 observations for each time point and the vertical bars represent ± S.E.M.
Figure 6:
Counts of total enzyme activity versus assay time. The muscle homogenates were prepared and enzyme assays with human skeletal muscle were performed as outlined in "Materials and Methods". The vertical bars represent S.E.M. and there were 14 observations for each point and the results are expressed as DPM/flask.
In other experiments, the same observations were made in heart (not shown). In the experiments it was demonstrated that by increasing the enzyme concentration to 300 μl (9.75 mg wet muscle) and extending the assay time to 4 or 5 min., it did not shift the line from linearity. As the assays were all run for only 2 min. and the maximal muscle added never exceeded 6.5 mg of muscle equivalent, the assay was linear with respect to time and concentration during these experiments. In fact, the enzyme activity was linear for at least 10 min. at 37°C (results not shown). The cofactor requirements for the PDH assay in muscle were characterized in more detail (Figures 7 and 8). There was less than 2% maximal activity without the presence of Mg²⁺ in skeletal muscle. Full activity was achieved by addition of 10 mM Mg²⁺, 10 mM Ca²⁺, 0.5 mM CoA, 30 mM NAD⁺, and 1.5 mM TPP. Omitting CoA, NAD⁺, or TPP decreased the activity by 75% and 80% respectively (Figure 7). The heart muscle responded to the lack of cofactors in a similar manner (Figure 8).

2. **Physiological Regulators of PDH Activation**

   A. **Nerve Stimulation in the Rat**

   The purpose of these experiments was to determine whether PDH activation could be mediated by nerve stimulation rather than a general hormonal effect.
**Figure 7.**

The effect of various cofactors on the activity of rat skeletal muscle PDH. The components and conditions were as described in "Materials and Methods". The PDH activity was measured over various time periods with and without certain cofactors as indicated. There were 10 samples for each time point.
Figure 8.
The effect of various cofactors on the activity of rat heart muscle PDH. The PDH activity was measured with and without cofactors over varying time periods. All conditions were as described in "Materials and Methods". There were 10 samples for each time point.
I The Effect of Sciatic Nerve Stimulation on Gastrocnemius Skeletal Muscle With a Constant Pulse Frequency and Voltage

The effect of electrical stimulation on PDH activity in rat gastrocnemius skeletal muscle is shown in Table 1. The PDH$_a$ at rest was 296 ± 15 nmol/g/min. and increased to 591 ± 29 nmol/g/min. after 1 min. electrical stimulation. The maximal PDH$_a$ activity was achieved after 10 min. of nerve stimulation. At this point more than 95% of the PDH$_t$ was in the active form.

Table 2 shows the effect of electrical stimulation on PDH activity in rat gastrocnemius skeletal muscle but during these experiments the muscle biopsies were obtained at more frequent intervals to detect the rapidity of the activation of PDH$_a$ conversion. The PDH$_a$ at rest was 276 ± 15 nmol/g/min., and electrical stimulation rapidly increased the PDH$_a$ activity. The PDH became activated linearly with time during the first 2 min. of nerve stimulation. Less rapid activation of PDH was shown after that (Table 2).

The PDH$_t$ did not change significantly during any of the experiments in Tables 1 and 2 with the average PDH$_t$ concentration for both being 840 ± 39 nmol/g/min. indicating that there was no significant muscle sampling errors.

The effect of electrical nerve stimulation on some key muscle metabolite concentrations is shown in Table 3.
<table>
<thead>
<tr>
<th>Time (Min.)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDH&lt;sub&gt;a&lt;/sub&gt; PDH&lt;sub&gt;t&lt;/sub&gt; (%)</td>
<td>36</td>
<td>67</td>
<td>77</td>
<td>91</td>
<td>92</td>
<td>97</td>
</tr>
<tr>
<td>PDH&lt;sub&gt;a&lt;/sub&gt; (nmol/g/min.)</td>
<td>296±15*</td>
<td>591±29</td>
<td>667±47</td>
<td>773±23</td>
<td>789±45</td>
<td>804±22</td>
</tr>
<tr>
<td>PDH&lt;sub&gt;t&lt;/sub&gt; (nmol/g/min.)</td>
<td>831±28</td>
<td>886±41</td>
<td>859±45</td>
<td>851±31</td>
<td>856±43</td>
<td>821±27</td>
</tr>
<tr>
<td>Observations</td>
<td>20</td>
<td>12</td>
<td>12</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

**Legend:** * mean ± S.E.M.

There were varied observations at each time period. The sciatic nerve was stimulated at a frequency of 10 pulses/sec. at 5 volts. PDH<sub>a</sub> and PDH<sub>t</sub> (PDH<sub>a</sub> + PDH<sub>t</sub>) was assayed as outlined in "Methods" section. Rat gastrocnemius skeletal muscle was used for each experiment. Controls were taken from the contralateral leg during each stimulation period. The results are expressed as nmol/g/min.
The results are expressed as nmoles/min. The experiments were done under controlled conditions during each experiment. The muscle was used for all the above experiments. Control muscles were assayed as outlined in Methods, Section, Gastrocnemius skeletal muscle. See Table 1 for effects on PFK and PFK-1 (PKA + PKI-1) was assessed. Static nerve was stimulated at a frequency of 10 pulses/sec. The nerve were varied observations at each time period. The

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>5</th>
<th>15</th>
<th>30</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFK-2 (umoles/mg)</td>
<td>792 ± 28</td>
<td>849 ± 36</td>
<td>636 ± 65</td>
<td>893 ± 35</td>
<td>836 ± 48</td>
</tr>
<tr>
<td>PFK-2 (umoles/mg)</td>
<td>276 ± 15</td>
<td>327 ± 11</td>
<td>337 ± 96</td>
<td>539 ± 38</td>
<td>555 ± 30</td>
</tr>
<tr>
<td>PFK-2 (umoles/mg)</td>
<td>35</td>
<td>47</td>
<td>51</td>
<td>60</td>
<td>66</td>
</tr>
</tbody>
</table>

**Table 2**

Effect of Static Nerve Stimulation on the Rapidity of Pyruvate Dephosphorylation Activity in Rat Gastrocnemius Skeletal Muscle
The table shows data collected from experiments on rat neurotransmitter metabolism before and after electric field stimulation. The activity of selected metabolites in extracts of rat brain was measured, and the data is presented in terms of mean ± S.E.M. Concentrations are listed for each metabolite and reported as amounts per mg of tissue at each time point. The values are given in ng/mg tissue for all measurements.

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>5</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>120</th>
<th>340</th>
<th>600</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>340</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The ATP concentration and the ATP:ADP ratio decreased significantly within 15 sec. after the start of nerve stimulation (Table 3). The CP concentration decreased to 10 from 17.9 μmol/g at 60 sec. and continued to decrease to 4.9 μmol/g after 10 min. of stimulation. The lactate concentration at rest was 1.3 μmol/g and increased at every time period, but after 2 min. it reached a peak concentration of 15.2 μmol/g. Pyruvate also increased as nerve stimulation progressed. At rest, the pyruvate concentration was 0.12 μmol/g and after 10 min. of the nerve stimulation the concentration increased to 0.39 μmol/g. The L:P ratio increased from 11 at rest to 35 after 10 min., however, the highest ratio was observed at 30 sec. The resting glycogen concentration was 37.2 μmol/g. Nerve stimulation was associated with a decrease in glycogen concentration during the entire stimulation period. The lowest concentration of 11.5 μmol/g was recorded after 10 min.

II The Effect of Sciatic Nerve Stimulation on Gastrocnemius Skeletal Muscle by Varying Pulse Frequency and Voltage

The following experiments extend the previous studies and show the effect of the stimulation rate on the activation of PDH in rat gastrocnemius skeletal muscle. The studies involved a varying pulse frequency of 5, 10 and 40
pulses/sec. at a constant voltage of 5 volts (Figure 9) and a constant 40 pulse frequency/sec. with a varying voltage of 5, 10 and 40 volts (Figure 10).

The resting PDH was essentially the same for all groups (Figures 9 and 10). Increasing the frequency of nerve stimulation increased the rate of PDH\textsubscript{a} formation. For example, at 30 sec. of nerve stimulation at 5 pulses/sec. resulted in 52% PDH\textsubscript{a} activation, while at 30 sec. of nerve stimulation at 40 pulses/sec. PDH was 83% activated.

The effect of changing the stimulation voltage at a constant pulse frequency is shown in Figure 10. The rate of PDH activation was slowest at 5 volts and the most rapid at 40 volts. At 120 sec. the three voltage groups had PDH\textsubscript{a} activated to over 90%.

As shown in Tables 4 and 5, tissue metabolites were determined in the freeze-clamped skeletal muscle at rest and at the end of each time period in only the rats which were treated by a nerve stimulation of 5 pulses/sec. at 5 volts, and 40 pulses/sec. at 40 volts respectively. The metabolite concentration changes were similar to those obtained earlier (Table 3), except that the metabolites which increased or decreased their concentration did so more slowly at a pulse frequency of 5/sec. than at 10/sec. The ATP, CP and glycogen concentrations decreased considerably in the 5 pulses/sec. at 5 volts stimulation while ADP,
Figure 9.

At 0 time the sciatic nerve of the rat was stimulated in a square wave fashion with 5 volts at a frequency of 40 pulses, 10 pulses and 5 pulses/second and pulse duration of 5 milliseconds. Gastrocnemius muscle biopsies were obtained at 0, 5, 15, 30, 60, 120, 240, 300, 600 seconds from the contralateral side and the stimulated leg. There were 6 stimulated observations for all time points. Each stimulated muscle sample was accompanied by a control sample. The control sample is the mean of 54 observations. The PDH₂ activity for 40 pulses/second and 5 volts was 306, 397, 439, 568, 697, 821, 831, 819, and 862 nmol/g/min from 0 to 600 seconds. For 10 pulses/second at 5 volts the PDH₂ activity was 296, 397, 433, 539, 591, 639, 773, 789 and 764 nmol/g/min. For 5 pulses/second at 5 volts the PDH₂ activity was 280, 330, 399, 460, 524, 634, 660, 667 and 697 nmol/g/min from 0-500 seconds. The PDH₄ averaged about 845 nmol/g/min. The vertical bars are ± S.E.M.
Figure 10.
For particulars of this experiment refer to Figure 9. In this case, however, the nerve was stimulated at a constant pulse but with a varied voltage. The pulses were 40/second but the voltage range was 80 volts, 10 volts and 5 volts respectively. Muscle biopsies were obtained at the same time periods but as the 120-240 second points were very similar to the 300 second period they were not included. There were 6 observations for the stimulated muscle at each point and a control was sampled with each. The PDH activity for 40 pulses/second at 40 volts was 312, 506, 759, 842, 826, 859 and 841 from 0-600 seconds respectively. For 40 pulses/second at 10 volts PDH was 287, 462, 676, 732, 804, 820, 847 from 0-600 seconds while for 40 pulses/second at 5 volts PDH was 313, 422, 531, 638, 760, 821, 840 from 0-600 seconds respectively. The PDH averaged about 865 nmol/g/min. The vertical bars are ± S.E.M.
The results are expressed in pmoles/min.

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>180</th>
<th>240</th>
<th>300</th>
<th>420</th>
<th>600</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.2</td>
</tr>
<tr>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.8</td>
</tr>
</tbody>
</table>

The concentration of monobutylate before and after...

Table 4
<table>
<thead>
<tr>
<th>0'</th>
<th>96</th>
<th>126</th>
<th>0'</th>
<th>96</th>
<th>126</th>
<th>0'</th>
<th>96</th>
<th>126</th>
<th>0'</th>
<th>96</th>
<th>126</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>17</td>
<td>33</td>
<td>95</td>
<td>17</td>
<td>33</td>
<td>95</td>
<td>17</td>
<td>33</td>
<td>95</td>
<td>17</td>
<td>33</td>
</tr>
</tbody>
</table>

There were 6 observations for each time period. The results were then extrapolated to the average.

### Table 3

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>400</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Scalae here stimulated in rat gastroceum secretion mucose.
pyruvate, lactate, and the L:P ratio increased (Table 4). When comparing the 40 pulses/sec. at 40 volts with the results above, Table 5 shows that all metabolite changes were similar, but the changes were more dramatic in response to the higher nerve stimulation. The ATP, CP, and glycogen concentrations and the ATP:ADP ratio showed a rather high degree of depletion while ADP, lactate, and pyruvate concentrations and the L:P ratio increased considerably.

III The Effect of Femoral Nerve Stimulation on Vastus Lateralis Skeletal Muscle By Varying Pulse Frequency and Voltage

These experiments using nerve stimulation on the rat were carried out in order to determine whether the nerve stimulation of another muscle group from a different nerve supply caused a variation in PDH activation. The vastus lateralis skeletal muscle from the quadriceps femoris group was stimulated via the femoral nerve. (Table 6)

The PDH in the vastus lateralis muscle increased in a manner which was similar to the gastrocnemius muscle response to nerve stimulation. (see Figure 9) The rate of increase of PDH activity was less with the vastus lateralis. This variation was not due to the pulse frequency or voltage applied to the nerve because the same conditions were used in both experiments. (see Figure 9) When the
pulse frequency was increased from 5 to 10 pulses/sec at 5 volts, the rate of PDHₐ formation was unaltered. (Tables 6 and 8)

In Tables 7 and 9 the metabolites measured displayed essentially the same concentrations at rest in the vastus lateralis as compared to the at rest gastrocnemius skeletal muscle, except for the glycogen concentration. The glycogen concentration in the vastus lateralis was 18 μmol/g compared to 38 μmol/g in the gastrocnemius muscle. (see Tables 4 and 5) The patterns of all the metabolites measured either increased or decreased in the vastus lateralis during nerve stimulation in a similar way to that observed in the gastrocnemius. (see Tables 4, 5, 7, and 9)

3. Aerobic Training in the Rat

Many studies in man and other mammalian species indicate that aerobic type training increases skeletal muscle capacity of O₂ consumption and CO₂ production. The purpose of the following experiments was to determine whether PDH adaptation could be a major factor for these observations. The role of PDH in the adaptive process has not yet been studied.

The effect of 10 weeks of aerobic training in skeletal muscle PDH activation is shown in Table 10. The PDHₐ activity was higher in the soleus than in the
Table 6

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>180</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>PT 1 (mEq/liter)</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
</tr>
<tr>
<td>PT 2 (mEq/liter)</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
</tr>
<tr>
<td>PT 3 (mEq/liter)</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
</tr>
<tr>
<td>PT 4 (mEq/liter)</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
<td>65 ± 5</td>
</tr>
</tbody>
</table>

Notes:
- The data are expressed in mEq/liter. The results were obtained in a group of 5 rats/pool. All values are the mean ± S.E.M. There were 3 observations for each time period. The femoral nerve was stimulated at a frequency of 5 pulses/sec. All injections were 4% saline in normal saline. The concentration in normal saline is 0.05 M. There were 5 observations for each time period.
### Experimental Design

#### Method of Measurement

- All results are expressed in J/mol at each temperature.
- Results were obtained from six observations each, at five voltages.
- The measurements were conducted under open circuit conditions.

### Table 7

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>Activity of Selected Enzymes after Incubation</th>
<th>Activity of Selected Enzymes before Incubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>600</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Note

- Activity measurements were conducted at each temperature.
- Results were obtained from six observations each, at five voltages.
### Table 8

Effect of Femoral Nerve Stimulation on Pyruvate Dehydrogenase Activation

In Rat Vastus Lateralis Skeletal Muscle Before and After Exercise

<table>
<thead>
<tr>
<th>Time (Sec.)</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{PDH}<em>{a}/\text{PDH}</em>{t}$ (%)</td>
<td>34</td>
<td>43</td>
<td>45</td>
<td>48</td>
<td>63</td>
</tr>
<tr>
<td>$\text{PDH}_{a}$ (nmol/g/min.)</td>
<td>$278 \pm 17^*$</td>
<td>$351 \pm 25$</td>
<td>$382 \pm 45$</td>
<td>$422 \pm 45$</td>
<td>$535 \pm 45$</td>
</tr>
<tr>
<td>$\text{PDH}_{t}$ (nmol/g/min.)</td>
<td>$819 \pm 27$</td>
<td>$820 \pm 33$</td>
<td>$859 \pm 60$</td>
<td>$844 \pm 53$</td>
<td>$845 \pm 22$</td>
</tr>
<tr>
<td>Observations</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

**Legend:**
* mean $\pm$ S.E.M. There were 8 observations for each time period. The femoral nerve was stimulated at a frequency of 10 pulses/sec, at 5 volts. All assays were as outlined in "Methods" section. Vastus lateralis skeletal muscle from the quadriceps group was used in each experiments. The results are expressed in nmol/g/min. The values for the resting muscle samples are from the unstimulated contralateral leg.
In each experiment, all results are expressed as % VM of wet mass.

Lactate, Pyruvate, ATP, ADP, GTP, and GTPase activities were assayed in methods section. Vastus lateralis skeletal muscle from the quadriceps of the rat was used at 5 v/f. All assays were outlined in methods section. Vastus lateralis stimulation of the femoral nerve was carried out at 10 pulses/sec. Stimulation of the femoral nerve was carried out at 10 pulses/sec.

Legend: * mean ± S.E.M. There were 8 observations for each time period.

<table>
<thead>
<tr>
<th>Time (sec)</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>-</td>
</tr>
<tr>
<td>Pyruvate</td>
<td>17.5 ± 2.4</td>
<td>17.5 ± 2.4</td>
<td>17.5 ± 2.4</td>
<td>17.5 ± 2.4</td>
<td>17.5 ± 2.4</td>
</tr>
<tr>
<td>ATP</td>
<td>1.4 ± 0.15</td>
<td>1.4 ± 0.15</td>
<td>1.4 ± 0.15</td>
<td>1.4 ± 0.15</td>
<td>1.4 ± 0.15</td>
</tr>
<tr>
<td>ADP</td>
<td>0.7 ± 0.03</td>
<td>0.7 ± 0.03</td>
<td>0.7 ± 0.03</td>
<td>0.7 ± 0.03</td>
<td>0.7 ± 0.03</td>
</tr>
<tr>
<td>GTP</td>
<td>4.7 ± 0.18</td>
<td>4.7 ± 0.18</td>
<td>4.7 ± 0.18</td>
<td>4.7 ± 0.18</td>
<td>4.7 ± 0.18</td>
</tr>
</tbody>
</table>

Table 9

Intermittent Rat Skeletal Muscle Before and After Femoral Nerve Stimulation

Selected Metabolite Concentrations from the Vastus
gastrocnemius. After 10 weeks of aerobic training the
PDHₜ activity was unchanged in either muscle group. However,
the resting PDHₜ in the soleus and gastrocnemius muscle was
increased by about twofold as a result of the 10 week
training programme.

4. Exercise in Human Skeletal Muscle In Vivo

The purpose of these experiments was to determine
the forms of exercise in man that might be important in the
regulation of skeletal muscle PDH activation.

A. Maximum Voluntary Isometric Contraction (MVIC)

Table 11 shows the results of skeletal muscle PDH
activity in human subjects contracting isometrically at 50%
MVIC. The PDHₐ at rest was 111 ± 3 nmol/g/min. while the
PDHₜ was 302 ± 3 nmol/g/min. The resting PDHₜ:PDHₐ was 37%.
After 10 sec. of contraction the PDHₐ increased only slightly
to 117 ± nmol/g/min. No significant changes in PDHₐ were
observed at 20, 30, or 60 sec. after contraction.

A number of key muscle intermediates were measured
and are summarized in Table 12. The ATP concentration
decreased progressively with time from 5.06 μmol/g at rest
to 2.90 μmol/g at exhaustion. The ADP concentration increased
from 0.57 μmol/g at rest to 0.78 μmol/g after only 10 sec.
but did not increase further thereafter. The ATP:ADP ratio
The results are expressed in runs/min. For further details see Methods section. The rats were run for 15 min twice daily, 5 days per week for 6 weeks. The animals were not exercised for 12 hours before mesenteric samples were taken by freeze-clamping with liquid N2 precooled tongs. For the last two weeks the rats were run for 15 min, at 90 meters per min. at 5% grade for 15 min. for 10 weeks and the work rate was increased weekly. During the last two weeks, an additional 45 min. on a motor-driven treadmill once daily, 5 days per week was added. All rats were trained on a motor-driven treadmill once daily, 5 days per week for 10 weeks before being tested. The rats in each condition were tested on 10 observations for each condition. The data are expressed as mean ± S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>10</th>
<th>10</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>950 ± 37</td>
<td>827 ± 22</td>
<td>960 ± 36</td>
<td>811 ± 22</td>
<td></td>
</tr>
<tr>
<td>778 ± 33</td>
<td>553 ± 28</td>
<td>362 ± 15</td>
<td>296 ± 15</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>66</td>
<td>39</td>
<td>36</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>10</th>
<th>10</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>950 ± 37</td>
<td>827 ± 22</td>
<td>960 ± 36</td>
<td>811 ± 22</td>
<td></td>
</tr>
<tr>
<td>778 ± 33</td>
<td>553 ± 28</td>
<td>362 ± 15</td>
<td>296 ± 15</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>66</td>
<td>39</td>
<td>36</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>10</th>
<th>10</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>950 ± 37</td>
<td>827 ± 22</td>
<td>960 ± 36</td>
<td>811 ± 22</td>
<td></td>
</tr>
<tr>
<td>778 ± 33</td>
<td>553 ± 28</td>
<td>362 ± 15</td>
<td>296 ± 15</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>66</td>
<td>39</td>
<td>36</td>
<td></td>
</tr>
</tbody>
</table>

Legend:
- (nmol/10 min) - mean ± S.E.M.
- (nmol/10 min) - mean ± S.E.M.
- (nmol/10 min) - mean ± S.E.M.
- (nmol/10 min) - mean ± S.E.M.
- (nmol/10 min) - mean ± S.E.M.

Table 10

In rat gastocromes and soybean seed with runtage aerodolytically induced changes of pyruvate dehydrogenase activity.
Table II
The Changes of Pyruvate Dehydrogenase Activity
By Exercise at 50% Maximum Voluntary Isometric
Contraction For Various Time Periods in Human
Quadrieps Femoris Skeletal Muscle In Vivo

<table>
<thead>
<tr>
<th>Exercise Time (Sec.)</th>
<th>PDH&lt;sub&gt;a&lt;/sub&gt;</th>
<th>PDH&lt;sub&gt;t&lt;/sub&gt;</th>
<th>A:T %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>111 ± 3* (23)</td>
<td>302 ± 3 (23)</td>
<td>37</td>
</tr>
<tr>
<td>10</td>
<td>117 ± 3 (4)</td>
<td>303 ± 2 (4)</td>
<td>39</td>
</tr>
<tr>
<td>20</td>
<td>129 ± 3 (5)</td>
<td>303 ± 4 (5)</td>
<td>42</td>
</tr>
<tr>
<td>30</td>
<td>137 ± 2 (5)</td>
<td>307 ± 2 (5)</td>
<td>45</td>
</tr>
<tr>
<td>69 ± 3 (Exhaustion)</td>
<td>127 ± 4 (8)</td>
<td>306 ± 2 (7)</td>
<td>44</td>
</tr>
</tbody>
</table>

Legend: * mean ± S.E.M. The subjects for each time period were exercised at 50% of their MIVC as outlined in "Methods". The number of observations are shown in brackets. The concentrations for PDH are expressed in nmol/g/min. For each exercise period a control sample was taken on the contralateral leg. The muscle biopsies were taken before exercise and immediately after the exercise ceased and frozen in liquid N<sub>2</sub>.
<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(9)</td>
<td>24.7±6.2</td>
<td>(9)</td>
<td>24.7±6.1</td>
<td>(9)</td>
<td>24.0±5.7</td>
<td>(9)</td>
</tr>
<tr>
<td>(7)</td>
<td>56.0±9.6</td>
<td>(9)</td>
<td>56.0±11.0</td>
<td>(9)</td>
<td>50.0±8.5</td>
<td>(9)</td>
</tr>
<tr>
<td>(9)</td>
<td>45.0±8.5</td>
<td>(5)</td>
<td>40.0±6.5</td>
<td>(5)</td>
<td>40.0±8.5</td>
<td>(5)</td>
</tr>
<tr>
<td>(9)</td>
<td>11.7±1.1</td>
<td>(5)</td>
<td>10.6±5.0</td>
<td>(5)</td>
<td>09.0±7.1</td>
<td>(5)</td>
</tr>
<tr>
<td>(9)</td>
<td>9.7±5.0</td>
<td>(9)</td>
<td>11.0±5.0</td>
<td>(9)</td>
<td>10.0±5.0</td>
<td>(9)</td>
</tr>
<tr>
<td>(5)</td>
<td>0.9±0.7</td>
<td>(9)</td>
<td>0.9±0.7</td>
<td>(9)</td>
<td>0.9±0.7</td>
<td>(9)</td>
</tr>
<tr>
<td>(9)</td>
<td>0.4±0.3</td>
<td>(9)</td>
<td>0.4±0.3</td>
<td>(9)</td>
<td>0.4±0.3</td>
<td>(9)</td>
</tr>
</tbody>
</table>

Exhaustion

Metabolite

Various Time Periods on Human Quadriceps Femoris Muscle Metabolite in Vivo

The Effect of 10% Maximum Voluntary Isometric Contraction for

Table 12
was lowest at exhaustion. The CP concentration decreased as contraction time increased, with 84% depletion occurring at exhaustion. As the CP concentration decreased the creatine concentration increased with the highest creatine concentration recorded at exhaustion. Muscle pyruvate accumulated at each exercise period and reached a peak concentration of $0.54 \pm 0.04 \mu \text{mol/g}$ at exhaustion.

The resting muscle lactate concentration was $1.8 \mu \text{mol/g}$ and increased with time. The concentration at exhaustion was $17.6 \pm 0.99 \mu \text{mol/g}$. The LiP ratio at rest was 23 and increased to 40 at exhaustion, but the highest ratio of 51 was observed after only 10 sec. of contraction.

The glycogen concentration also decreased with time with 39% depletion of muscle glycogen stores occurring at exhaustion.

**B. Progressive Exercise**

The effect of progressively increasing aerobic exercise on the activation of human skeletal muscle PDH is shown on Table 13. At rest the PDH$_a$ activity was $124 \pm 9$ nmol/g/min. which was 40% of the PDH$_t$. At exhaustion, after approximately 20 min. of exercise, and when the subject was working at about 90% VO$_2$ max, the PDH$_a$ activity increased more than twofold to $260 \pm 7$ nmol/g/min. Virtually all the PDH was in the active form at exhaustion.
<table>
<thead>
<tr>
<th>Rest</th>
<th>PILR</th>
<th>PILR</th>
<th>PILR</th>
<th>PILR</th>
<th>PILR</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>7</td>
<td>9</td>
<td>301</td>
<td>4</td>
<td>398</td>
</tr>
<tr>
<td>118</td>
<td>7</td>
<td>24</td>
<td>321</td>
<td>4</td>
<td>294</td>
</tr>
<tr>
<td>60</td>
<td>2</td>
<td>2</td>
<td>321</td>
<td>4</td>
<td>26</td>
</tr>
<tr>
<td>39</td>
<td>9</td>
<td>3</td>
<td>99</td>
<td>5</td>
<td>98</td>
</tr>
<tr>
<td>99</td>
<td>5</td>
<td>8</td>
<td>108</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>118</td>
<td>7</td>
<td>2</td>
<td>321</td>
<td>4</td>
<td>26</td>
</tr>
<tr>
<td>60</td>
<td>2</td>
<td>2</td>
<td>321</td>
<td>4</td>
<td>26</td>
</tr>
<tr>
<td>39</td>
<td>9</td>
<td>3</td>
<td>99</td>
<td>5</td>
<td>98</td>
</tr>
<tr>
<td>99</td>
<td>5</td>
<td>8</td>
<td>108</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

The columns are in the method. The number of observations is shown on the position time. The observations in each type of exercise were exerted to exhaustion to exhaustion.

<table>
<thead>
<tr>
<th>Observations</th>
<th>PILR</th>
<th>PILR</th>
<th>PILR</th>
<th>PILR</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>7</td>
<td>9</td>
<td>301</td>
<td>4</td>
</tr>
<tr>
<td>118</td>
<td>7</td>
<td>24</td>
<td>321</td>
<td>4</td>
</tr>
<tr>
<td>60</td>
<td>2</td>
<td>2</td>
<td>321</td>
<td>4</td>
</tr>
<tr>
<td>39</td>
<td>9</td>
<td>3</td>
<td>99</td>
<td>5</td>
</tr>
<tr>
<td>99</td>
<td>5</td>
<td>8</td>
<td>108</td>
<td>4</td>
</tr>
<tr>
<td>118</td>
<td>7</td>
<td>2</td>
<td>321</td>
<td>4</td>
</tr>
<tr>
<td>60</td>
<td>2</td>
<td>2</td>
<td>321</td>
<td>4</td>
</tr>
<tr>
<td>39</td>
<td>9</td>
<td>3</td>
<td>99</td>
<td>5</td>
</tr>
<tr>
<td>99</td>
<td>5</td>
<td>8</td>
<td>108</td>
<td>4</td>
</tr>
</tbody>
</table>

In vivo, on the motion of human skeletal muscle, the forearm movement effect of various types of work on a cycle ergometer.

Table 1

In vivo, on the motion of human skeletal muscle, the forearm movement effect of various types of work on a cycle ergometer.
C. Intermittent Exercise

The effect of intermittent short-term heavy exercise (140% \( V\text{O}_2 \text{ max} \)) until exhaustion is summarized in Table 13. The PDH\(_{a}\) increased from 122 to 193 nmol/g/min. at exhaustion. Despite the increased duration of the exercise period and the increased work accomplished, there was significantly less PDH activation than with the progressive exercise workload.* At exhaustion, about 30-40 min. after the start of the exercise, only 60% of the PDH\(_{t}\) was in the active state.

D. Short Term Maximal Exercise

The effect of the anaerobic-type exercise at the subjects' \( V\text{O}_2 \text{ max} \) on muscle PDH activation is shown in Table 13. The resting PDH\(_{a}\) activity was 108 ± 4 nmol/g/min. and increased to 118 ± 3 nmol/g/min. at exhaustion (exercise time: 65, 69, and 73 sec.). The change was not significantly different from the values obtained at rest. Essentially the same results were obtained with 50% maximum voluntary isometric contraction. (Table 11)

In all types of exercise situations the PDH\(_{t}\) did not change at rest or after exhaustive exercise suggesting that no significant errors in sampling of the muscle occurred.

* Progressive Exercise = 1700±200 Kpm/min.; Intermittent Exercise = 2500 ± 180 Kpm/min.
The effect of the various exercise regimes on muscle metabolite concentrations are summarized in Table 14. The muscle pyruvate concentration increased threefold from $0.07 \pm 0.01$ to about $0.20 \pm 0.03 \mu \text{mol/g}$ in both progressive and intermittent exercise, while after short term exercise it increased slightly more, to $0.27 \pm 0.02 \mu \text{mol/g}$. The lactate concentration increased sevenfold in progressively increasing workload exercise, twelvefold in intermittent exercise, and with short term maximal exercise to exhaustion, it increased almost fifteenfold. The L:P ratio increased at the end of every work situation with the highest ratio increase of over fourfold being recorded with intermittent exercise.

There was a marked decrease in CP concentration with exercise which was associated with a parallel increase in the creatine concentration in each exercise group. The glycogen concentration with exercise in all three work regimens decreased, with the greatest decrease shown in the intermittent exercise.

E. Heavy Resistance Weight Training, Immobilization In Human Triceps Brachii Skeletal Muscle

The purpose of this study was to determine the effects of long-term heavy resistance weight training and 5 week long immobilization on skeletal muscle PDH activity.
<table>
<thead>
<tr>
<th>Observation</th>
<th>5</th>
<th>5</th>
<th>6</th>
<th>9</th>
<th>6</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.92 ± 2.52</td>
<td></td>
<td></td>
<td></td>
<td>16.4 ± 7.49</td>
<td>7.4 ± 3.4</td>
<td>17.4 ± 7.2</td>
</tr>
<tr>
<td>7.9 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td>16.4 ± 7.49</td>
<td>7.4 ± 3.4</td>
<td>17.4 ± 7.2</td>
</tr>
<tr>
<td>7.9 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td>16.4 ± 7.49</td>
<td>7.4 ± 3.4</td>
<td>17.4 ± 7.2</td>
</tr>
<tr>
<td>7.9 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td>16.4 ± 7.49</td>
<td>7.4 ± 3.4</td>
<td>17.4 ± 7.2</td>
</tr>
<tr>
<td>7.9 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td>16.4 ± 7.49</td>
<td>7.4 ± 3.4</td>
<td>17.4 ± 7.2</td>
</tr>
</tbody>
</table>

In human subjects, muscle at rest and after exhaustive exercise on a cycle ergometer.

Effect of various types of work on tissue metabolic concentrations.
and determine whether this might explain the capacity of muscle to oxidize pyruvate with this type of training or be reversed by immobilization. The study was conducted as outlined in the "Methods" on p. 46.

I. Study 1 - (Group 1 and 2)

(a) Group 1: The muscle biopsies were taken from the arm in the following order: control, after 20 week training and following 5 week immobilization. (Figure 11) The control PDH<sub>a</sub> activity was 107 ± 3 nmol/g/min. (PDH<sub>a</sub>:PDH<sub>t</sub> ratio 35%), while post training PDH<sub>a</sub> had increased to 166 ± 10 nmol/g/min. (PDH<sub>a</sub>:PDH<sub>t</sub> ratio 54%). After 5 weeks of immobilization after the training period, the PDH<sub>a</sub> decreased to 48 ± 2 nmol/g/min. The PDH<sub>t</sub> activity was unaffected by the training or the immobilization.

(b) Group 2: The muscle biopsies were taken from the arm in the following order: control, after 5 weeks of immobilization and after 20 weeks of training. The resting control PDH<sub>a</sub> was 108 ± 4 nmol/g/min. similar to values obtained in Group 1. The PDH<sub>a</sub>:PDH<sub>t</sub> ratio was 36%. The PDH<sub>a</sub> after 5 weeks of immobilization decreased to 38 ± 4 nmol/g/min. with a PDH<sub>a</sub>:PDH<sub>t</sub> ratio of 12%. The immobilization programme, where it preceded the training period, resulted in substantially lower PDH<sub>a</sub> activation (48 ± 2 vs 38 ± 4 nmol/g/min.).
Figure II.

I. The effect of training and immobilization upon PDH_{2} and PDH_{1} activity in human triceps brachii skeletal muscle. The training was with weights for 5 months and immobilization was by placing the arm in a cast for 5 weeks. Muscle biopsies were taken before and after training and immobilization. There were 4 observations for each variable in I.

II. The particulars are as for above (I), but were in reverse order. The vertical bars are ±S.E.M. and there were 5 observations for each variable in II.
After the 20 week weight training programme was completed, the PDH_a had increased to 179 ± 9 nmol/g/min. while the PDH_a:PDH_t ratio was 55%. (Figure 11)

(i) Metabolites: (Group 1 and 2)

The concentration of both CP and creatine were significantly higher (p < 0.05) after weight training in both groups (Table 15), while CP concentrations decreased significantly if both groups following immobilization. The decreases in concentration of creatine were only significant in group 1 where immobilization proceeded training even though both groups had decreases in creatine.

The ATP concentrations were significantly higher in both groups following training (p < 0.05) but were not significantly affected by immobilization.

When the training ATP and CP concentrations were combined and considered as total phosphagen, the phosphagen pool increased by 13% as a result of training. After immobilization, the phosphagen concentration decreased 18% from 44.7 to 36.1 μmol/g (p < 0.05). The muscle glycogen concentration increased from 86 ± 7 to 114 ± 11 μmol/g (p < 0.01) as a result of training (Groups 1 and 2). Immobilization decreased the muscle resting glycogen from 86 ± 7 to 57 ± 10 μmol/g (p < 0.01). Immobilization, when it proceeded the training programme resulted in a larger
Values are mean ± S.E.M. and are expressed in μmol/8 wet wt. µ

<table>
<thead>
<tr>
<th>Glycogen</th>
<th>Pyruvate</th>
<th>Lactate</th>
<th>ADP</th>
<th>ATP</th>
<th>Creatine</th>
<th>CP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.56 ± 0.09</td>
<td>6.96 ± 1.25</td>
<td>0.17 ± 0.05</td>
<td>0.82 ± 1.12</td>
<td>0.08 ± 0.52</td>
<td>1.18 ± 0.72</td>
<td>0.70 ± 0.12</td>
</tr>
<tr>
<td>0.42 ± 0.06</td>
<td>0.30 ± 0.10</td>
<td>0.15 ± 0.05</td>
<td>0.82 ± 0.51</td>
<td>0.08 ± 0.52</td>
<td>1.18 ± 0.72</td>
<td>0.70 ± 0.12</td>
</tr>
<tr>
<td>1.56 ± 0.09</td>
<td>6.96 ± 1.25</td>
<td>0.17 ± 0.05</td>
<td>0.82 ± 1.12</td>
<td>0.08 ± 0.52</td>
<td>1.18 ± 0.72</td>
<td>0.70 ± 0.12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post</td>
<td>Post</td>
</tr>
</tbody>
</table>

**Table 1**

Concentrations of Metabolites Before and After Training and Implantation
decrease in the muscle glycogen concentration (Group 1: 102 ± 7 to 55 ± 11; Group 2: 88 ± 9 to 59 ± 9 μmol/g) (p < 0.01).

F. Heavy Resistance Weight Training, Immobilization and Exercise in Human Triceps Brachii Skeletal Muscle

The second study was similar to Groups 1 and 2 (p. 46) except muscle biopsies were also obtained after arm cranking exercise to exhaustion and the immobilization was extended from 5 to 6 weeks.

I. Study 2: (Groups 3 and 4)

(a) Group 3: Resting and exercise muscle biopsies were obtained in the following sequence: control, after 20 weeks weight training and then 6 weeks after immobilization began.

The resting control PDH_a was 111 ± 4 nmol/g/min. and the PDH_a:PDH_t ratio was 37%. (Figure 12) After exercise the PDH_a increased to 288 ± 6 nmol/g/min. and the PDH_a:PDH_t ratio was 95%. As a result of the 20 weeks weight training programme, the PDH_a increased to 198 ± 7 nmol/g/min. at rest and the PDH_a:PDH_t ratio was 65%. Immediately after exercise the PDH_a was 295 ± 6 nmol/g/min. with 97% in the active form. After 6 weeks of immobilization the resting
Figure 12.

III. Effect of training, immobilization and exercise upon PDH$\alpha$ and PDH$\beta$ activity in human triceps brachii skeletal muscle. The biopsies were obtained at rest, after training and after immobilization and after exercise at each variable. There were 3 observations for each variable. The vertical bars are ± S.E.M. For further particulars see "Materials and Methods".

IV. Muscle biopsies were taken in a different order from Study III. At rest, after immobilization and after training and after exercise at each variable. There were 3 observations at each variable. The vertical bars are ± S.E.M. For further particulars see "Materials and Methods".
PDH\textsubscript{a} decreased dramatically to $35 \pm 3$ nmol/g/min. or 11\% of the PDH\textsubscript{t} activity. Exercise following the immobilization period increased the PDH\textsubscript{a} to $158 \pm 9$ nmol/g/min. with only 53\% in the active form. The muscle PDH\textsubscript{t} activity was not altered during any of these experimental conditions.

(b) Group 4: In this series of experiments resting and exercise biopsies were obtained under control conditions, after 6 weeks of immobilization and after 20 weeks of weight training. The concentration of the control PDH\textsubscript{a} was $113 \pm 5$ nmol/g/min. and increased to $279 \pm 10$ nmol/g/min. after exercise. (Figure 12) After the 6 weeks immobilization the PDH\textsubscript{a} decreased to $20 \pm 4$ nmol/g/min or a PDH\textsubscript{a}:PDH\textsubscript{t} ratio of 6\%. Following exercise the PDH\textsubscript{a} activity increased to $151 \pm 12$ nmol/g/min. with 50\% of the PDH\textsubscript{t} activity in the active form. After the 20 week training programme the resting PDH\textsubscript{a} was $224 \pm 14$ nmol/g/min. with the PDH\textsubscript{a}:PDH\textsubscript{t} ratio of 73\%. After exercise the PDH\textsubscript{a} activity increased to $299 \pm 6$ nmol/g/min. or 98\% of the PDH\textsubscript{t} activity. In summary, immobilization markedly decreased PDH\textsubscript{a} activity while weight training increased it well above control levels. Arm exercise after immobilization resulted in minimal PDH activation while training resulted in rapid activation with exercise. No changes in PDH\textsubscript{t} activity were observed.
(i) **Metabolites: (Groups 3 and 4)**

All the metabolite control resting values were similar to those obtained in Study 1 (see p. 104 and 105). Immobilization, whether it preceded or followed the training regime, significantly decreased the resting muscle CP concentration ($p < 0.05$). (Table 16) There was no consistent trend in the resting ATP concentration as a result of immobilization. Glycogen content was significantly altered by immobilization. The glycogen, ATP and CP concentration increased significantly as a result of the training programme. Immobilization followed the training, decreased the glycogen, ATP and CP concentration but only CP was below the values obtained in the control state.

Exercise, at the same workload and for the same time period (control and training) resulted in similar CP concentration decreases. Similarly, the decrease in ATP concentration as a result of exercise was essentially the same in control and after training. However, after immobilization with a reduced workload but over the same time period, the CP concentration was decreased most while ATP was essentially the same. The rise in muscle lactate with work was greatest after immobilization even though the workload was reduced. The absolute change in muscle glycogen ($37 \mu$ mol/g) was similar in all the groups.
<table>
<thead>
<tr>
<th>Bx</th>
<th>Treatment</th>
<th>Ex Post</th>
<th>Ex Pretreatment</th>
<th>Ex Post</th>
<th>Ex Pretreatment</th>
<th>Ex Post</th>
<th>Ex Pretreatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Group 1</td>
<td>N = 7</td>
<td>Tasting</td>
<td>Immobilization</td>
<td>Tasting</td>
<td>Immobilization</td>
<td>Tasting</td>
</tr>
</tbody>
</table>

Table 16
5. Role of Hormonal Factors in Activating Skeletal Muscle PDH

A. A Comparison Between Unstimulated and Stimulated Pyruvate Dehydrogenase In Human and Rat Skeletal Muscle

This study was done to determine if PDH activation during exercise was hormonally induced or initiated by local muscle factors.

The human skeletal muscle non-exercised contralateral leg showed no PDH activation while in the exercising leg the PDH activity increased about twofold. (Figure 13)

In rat skeletal muscle the nerve stimulated leg showed a twofold activation of PDH within 1 min. while the non-stimulated contralateral leg at the same time showed no PDH activity. (Figure 13)

In both human and rat skeletal muscle the PDH did not change in either leg.

6. Effect of Various Factors on PDH Activation In the Perfused Rat Heart

The heart was used as a model for pyruvate oxidation and PDH activation because the oxidative rate in the heart varies by about threefold. The degree of PDH activation that might occur under these circumstances is roughly the
Figure 13.

Left: Three male subjects performed unilateral exercise on a cycle ergometer at 800 kpm for 2 minutes. The human skeletal muscle biopsies for PDH activity were taken at rest in both right and left legs and after exercise in the exercised and non-exercised leg. The vertical bars are ± S.E.M.

Right: Rat skeletal muscle was obtained from the vastus muscle group and the gastrocnemius muscle (not shown) after unilateral nerve stimulation. The PDH activity was measured at rest in both legs and after exercise in the exercised and non-exercised leg. There were 10 observations for each leg including the gastrocnemius muscle (not shown). The results were similar for both muscle groups. The nerve stimulation was performed in square wave fashion at 40 pulses/second at 5 volts and a duration of 5 milliseconds for 1 minute. The vertical bars are ± S.E.M.
same. The author is aware that factors other than PDH activation may regulate heart pyruvate oxidation but the model was used in order to determine whether the major changes in the rate of pyruvate oxidation in heart could be explained by PDH activation alone.

The effect of epinephrine (1.3 μg/ml) on the rate of heart pyruvate oxidation is outlined in Figure 14. The PDH<sub>a</sub> increased from 1220 to a maximum of 4500 nmol/g/min. at 3-6 min. after addition of epinephrine. There was a similar increase in the rate of heart pyruvate oxidation from 1502 at 0 time to a maximum of 2960 nmol/g/min. at 6 min. after starting epinephrine infusion. The degree of PDH activation decreased between 6-9 min. after the start of epinephrine infusion with similar decreases in the rate of heart pyruvate oxidation. After starting the infusion of epinephrine the cyclic AMP increased from 330 fmol/μg DNA to a maximum of 944 at 9 min. (Figure 15) No significant difference of cAMP concentration was noted between 6-9 min. after the start of the epinephrine infusion. The PDH<sub>a</sub> activity was increased by about fourfold by epinephrine while the rate of pyruvate oxidation increased about twofold.

When propranolol (4 μg/ml) and epinephrine (1.3 μg/ml) were infused together, the PDH activation was much less than with epinephrine alone. (Figure 16) There was a small increase in PDH<sub>a</sub> activity suggesting that the propranolol
Figure 14.

Fasted rats (200-250 g) were anesthetized with ether and the hearts were removed after I.V. injection of heparin. The hearts were perfused through the aorta at a pressure of 80 mmHg for 10 min. with KRB. Epinephrine (1.3μg/ml) was then infused and the hearts perfused for 1, 3, 6, or 9 min., and at end of time period, the heart was freeze-clamped. The rat heart muscle homogenate of approximately 100 mg wet weight was assayed for active and total PDH and pyruvate oxidation was also determined. The PDH reached 5048 nmol/g/min. All other procedures refer to "Materials and Methods." The means ± S.E.M. are shown on figure and the number of observations as indicated at each time point.
Figure 15.
Perfused rat heart muscle homogenates were assayed for PDH activity and cAMP concentrations after treatment with 1.3 μg/ml epinephrine as described in Figure 14, and "Materials and Methods". The number of observations are as indicated at each point and the vertical bars represent ± S.E.M. The total PDH averaged 5048 nmol/g/min.
Figure 16.
Perfused rat heart muscle homogenates were assayed for changes in pyruvate oxidation and PDH activity over various time periods after treatment with 1.3 μg epinephrine and 4 μg/ml propranolol. The number of observations are as indicated and the vertical bars are ± S.E.M. All conditions of the experiments are as in "Materials and Methods" and Figure 14. The average total PDH was 4789 nmol/g/min.
was not present in a dose high enough to block the effect of epinephrine on PDH activation. The inhibition of PDH activation was followed in a parallel manner in that the rate of heart pyruvate oxidation was not changed. (Figure 16) The combination of epinephrine and propranolol almost completely prevented the activation of PDH, but the heart cAMP concentration increased substantially despite the ability of propranolol to block the activation of PDH. (Figure 17)

Propranolol alone had no effect on PDH activation, pyruvate oxidation (Figure 18), or on the heart cAMP concentration (Figure 19).

Insulin (1 mU/ml) resulted in almost complete activation of heart PDH (Figure 20) within 6 min. of insulin addition. The rate of pyruvate oxidation increased by about 100%. While insulin resulted in PDH activation, no changes in heart cAMP concentration were observed. (Figure 21)

The conditions of the heart perfusions described above did not involve pacing; spontaneous heart frequency varied between 120-160 beats/min. When the heart was electrically stimulated at 5 volts at a pulse frequency of 300 beats/min., there was rapid activation of PDH, with almost complete activation of the enzyme by 60 sec. of stimulation. (Figure 22) A similar increase in the rate of heart pyruvate oxidation was observed.
Figure 17.

Rat heart perfused with 1.3 μg/ml epinephrine and 4 μg/ml propranolol were homogenized and assayed for PDH activity and cAMP concentration. Hearts were freeze-clamped at various time periods and the number of observations were as indicated. The vertical bars are ± S.E.M. The total PDH averaged 4789 Amol/g/min.
Figure 18.

Oxidation of pyruvate and PDH$_a$ activity was measured as described in "Materials and Methods" and Figure 14, except the hearts were perfused with 4 µg/ml propranolol only. Each point represents a time period and 8 observations. The vertical bars are ± S.E.M. The total PDH activity averaged 4860 nmol/g/min.
Figure 19.

PDH$_a$ activity and cAMP concentration was measured from freeze-clamped perfused rat hearts treated with 4 $\mu$g/ml propranolol at various time periods. There were 8 observations at each point and the vertical bars are $\pm$ S.E.M. For other particulars refer to "Materials and Methods" and Figure 14. The total PDH activity averaged 4860 nmol/g/min.
Figure 20.
Rat hearts were perfused with insulin (1 μU/ml) over various time periods and freeze-clamped. The homogenates were assayed for PDHₐ activity. Pyruvate oxidation was also determined and the experimental conditions are as described in "Materials and Methods" and Figure 14. The PDHₐ activity averaged 4942 nmol/g/min. There were 8 observations at each time period and the vertical bars are ± S.E.M.
Figure 21.

Rat hearts were perfused with insulin (1 mU/ml) and the PDH activity and cAMP concentrations were measured. The PDH averaged 4942 nmol/g/min, and there were 8 observations at each time period. The conditions of the experiments are as described in the "Materials and Methods" and Figure 14. The vertical bars are ± S.E.M.
Figure 22.

Rat hearts were perfused, and paced by electrical stimulation which produced 300 beats/minute over 30 and 60 second time periods. The hearts were freeze-clamped, homogenized and assayed for PDH$_a$ and pyruvate oxidation also measured as in "Materials and Methods". The vertical bars are ± S.E.M. and there were 8 observations at each time point for PDH and 4 observations for the measurement of pyruvate oxidation at each point. The total PDH activity averaged 4548 nmol/g/min.
FPA oxidation in heart inhibits cell glucose entry and oxidation. In the experiments outlined in Figure 23, 1.0 mM octanoic acid resulted in marked decrease in the PDH activity. The rate of pyruvate oxidation was not decreased in a similar way. Octanoic acid resulted in a decrease in the heart cAMP concentration. (Figure 24)

The effect of pyruvate concentration (a substrate for pyruvate dehydrogenase) on PDH activation is shown in Figure 25. Almost complete activation of PDH was observed within 2-3 min. of 200 μM pyruvate addition. The rate of pyruvate oxidation was increased but the extent of the increase was less than the degree of PDH activation. The effect of 200 μM pyruvate on heart cAMP concentration is shown in Figure 26. It increased from 372 to 934 fmol/μg DNA within 9 min. of pyruvate addition. (Figure 26) Increasing the pyruvate concentration to 1 mM resulted in the same rate and extent of PDH activation, as 200 μM pyruvate. (Figure 27) The rate of pyruvate oxidation was increased by 1 mM pyruvate to a greater extent than 200 μM pyruvate. (Figure 25 and 27) The heart cAMP concentration was increased by about threefold by the 1 mM pyruvate. (Figure 28)

In order to determine whether PDH activation could account for the observed increase in pyruvate oxidation, the extent of PDH formation was correlated with the observed rates of pyruvate oxidation. (Figure 29) The
correlation of PDH activation and rate of pyruvate oxidation was greater than ($r = 0.92$), when all agents were compared and plotted.
Figure 23.
Perfused rat hearts treated with octanoic acid (1 mM) were freeze-clamped at each time point and the activity of PDH$_a$ and changes in pyruvate oxidation were measured. There were 8 observations at each time period and the vertical bars are ± S.E.M. The total PDH averaged 496 ± nmol/g/min.
Figure 24.
Perfused rat hearts treated with octanoic acid (1 mM) were freeze-clamped and assayed for PDH activity and cAMP concentration. The total PDH activity averaged 490 nmol/g/min. There were 8 observations at each time period and the vertical bars are ± S.E.M. All other conditions are as in "Materials and Methods".
Figure 25.

The perfused hearts were treated with 200 μM pyruvate, freeze-clamped and the homogenates were assayed for PDH activity and pyruvate oxidation changes. The hearts were perfused for either 1, 1.5, 2, 3, 4.5, 6 or 9 minutes and there were 8 observations at each time point. The results are presented as ± S.E.M. The PDH activity averaged 4694 nmol/g/min.
Figure 26.
The effect of 200 μM pyruvate infused into the rat heart is shown in this figure. The homogenate was assayed for PDH and cAMP concentration after a perfusion of 1, 1.5, 2, 3, 4.5, 5, 6, and 9 minutes. The PDH activity averaged 4694 nmo1/g/min. in these experiments. There were 9 observations at each time point and the vertical bars are ± S.E.M.
RAT HEART MUSCLE
1 mM PYRUVATE

Figure 27.
Effects of 1 mM pyruvate on the activity of PDH$_a$ in the perfused rat heart and the rate of pyruvate oxidation. Assays for PDH$_a$ are as for Figure 14 and in "Materials and Methods". The total PDH activity averaged 4979 nmol/g/min. The perfusion times were 3, 6, and 9 minutes. The results are shown as mean ± S.E.M. and there were 8 observations at each time point.
Figure 28.
Effects of 1 mM pyruvate on cAMP concentration and PDH activity in perfused rat heart homogenates. There were 8 observations for each time point and the perfusion was over 3, 5, 6, and 9 minutes for cAMP, and 3, 6, and 9 minutes for PDH. The PDH averaged 4979 nmol/g/min. The vertical bars are ± S.E.M. All other conditions are as in Figure 14 and in the "Materials and Methods".
Figure 29.
The experimental results from all groups were compiled and plotted as PDH_a versus the rate of pyruvate oxidation. The rate of pyruvate oxidation was calculated from the rate of $^{14}$CO$_2$ production after correction for changes in heart specific activity. This was determined by converting pyruvate to alanine by alanine dehydrogenase and separating the alanine on a cation exchange resin column. Correlation resulted in an $r = 0.92$. 
Symbols (Key) for Figure 29

- 20 μM Pyruvate (Control)
- 50 μM Pyruvate (Control)
- 200 μM Pyruvate (Control)
- 1000 μM Pyruvate (Control)
- 1.3 μg/ml Epinephrine + 20 μM Pyruvate
- 1.3 μg/ml Epinephrine + 50 μM Pyruvate
- 1 mU/ml Insulin + 20 μM Pyruvate
- 1 mU/ml Insulin + 50 μM Pyruvate
- 4 μg/ml Propranolol + 20 μM Pyruvate
- 4 μg/ml Propranolol + 200 μM Pyruvate
- 4 μg/ml Propranolol + 1000 μM Pyruvate
- 1.3 μg/ml Epinephrine + 4 μg Propranolol + 20 μM Pyruvate
- 1 mM Octanoic Acid + 20 μM Pyruvate
- Electrical Stimulation of Heart (Pacing) + 20 μM Pyruvate
DISCUSSION

1. Methodology

Pyruvate dehydrogenase activity was assayed by the formation of $^{14}\text{CO}_2$ from pyruvate-$l-^{14}\text{C}$ in muscle homogenates by a modification of the method described by Taylor et al., 1973. By comparing the homogenate method with the mitochondrial preparation of Taylor et al. and Taylor and Halperin, 1973, it was found that the homogenate preparation provided essentially the same results for the $\text{PDH}_\text{a}:\text{PDH}_\text{t}$ ratio. If a mitochondrial preparation was used, a considerable amount of tissue and time was required with less than 10% recovery of mitochondria. Because of this low mitochondria yield, it was not possible to measure PDH activity in the isolated mitochondrial fraction from less than 50 mg of skeletal muscle biopsy.

The experiments comparing the homogenate and the mitochondrial preparations indicated that the rate of $^{14}\text{CO}_2$ production from pyruvate-$l-^{14}\text{C}$ was linear with time and enzyme concentration (p. 70). Separate experiments indicated that PDH activity of a homogenate did not change during 60 min. of storage on ice. This suggests that there was no net enzyme phosphorylation or dephosphorylation. Since the time period between homogenization and enzyme
assay did not exceed 10 min., the observed PDH<sub>a</sub>:PDH<sub>b</sub> ratio probably reflects the state of the enzyme in vivo.

PDH activity requires a number of cofactors for its full activity (p. 74). The significance of the cofactors on the homogenate PDH activity is illustrated by the results on p. 75. Mg<sup>++</sup> and Ca<sup>++</sup> were essential for the full activity of the enzyme. The maximum activity of PDH was achieved with 10 mM MgCl<sub>2</sub> and 10 mM CaCl<sub>2</sub>. The addition of lower CaCl<sub>2</sub> concentrations (10-1.0 mM) did not have a major effect on the PDH activity. Other direct evidence that the assay does measure the PDH activity was provided by the observations that 14CO<sub>2</sub> liberated required the following cofactors - TPP, CoA and NAD<sup>+</sup> (p. 75). When NAD<sup>+</sup> or CoA were omitted separately, there still was considerable PDH activity. As NAD<sup>+</sup> and CoA are essential cofactors for PDH activity these observations suggest that some NAD<sup>+</sup> and CoA was bound to the enzyme complex. 51

The spontaneous decarboxylation of pyruvate produced significant problems in determining the 14CO<sub>2</sub> produced from pyruvate-1-14C. This was circumvented by minimizing the decarboxylation of pyruvate-1-14C by freeze-drying the pyruvate-1-14C and storing it dry in sealed vials at -20°C until required. Using these precautions, the basal 14CO<sub>2</sub> present prior to the assay was less than 5% of the DPM at the end of the assay. If these precautions were not
considered, the background $^{14}\text{CO}_2$ present at 0 time was not much lower than the $^{14}\text{CO}_2$ present at the end of the incubation. Such experimental conditions would not permit one to measure PDH activation with any accuracy.

2. **Skeletal Muscle**

PDH regulates and catalyzes the decarboxylation of pyruvate to form acetyl CoA.\textsuperscript{1,8,9,13a,13b} In skeletal muscle the enzyme's activity is a major determinant affecting pyruvate oxidation from glycogen and blood glucose. Though the activity of the enzyme could be of major regulatory importance in regulating lipogenesis, in this regard, it is probably of little significance in skeletal muscle, since muscle capacity for lipogenesis is very small.\textsuperscript{211-213} PDH activity is clearly of importance in regulating the oxidation of amino acids which have pyruvate as one of the intermediate steps. However, this is probably of little quantitative significance since amino acid oxidation forms a very small fraction of muscle pyruvate oxidation at rest or exercise.

Heavy aerobic exercise perhaps places the greatest demand on the muscle capacity to oxidize energy producing substrates. Work at close to the $V_0_2$ max results in 20-50 fold increases in the muscle $O_2$ consumption.\textsuperscript{205-208,211,212} Most of the substrate for this is pyruvate derived from muscle glycogen and blood glucose.\textsuperscript{207-209} Light work, on
the other hand, results in a relatively small increase in muscle $O_2$ consumption. In this case, some of the substrate oxidized is carbohydrate, but the majority of the $CO_2$ is derived from oxidation of fat, probably derived from increased lipolysis seen in these circumstances. Because heavy work results primarily in muscle carbohydrate oxidation it would appear that regulation of PDH activity plays a major role in regulating pyruvate oxidation derived from glucose or glycogen. With heavy work, the flow through the enzyme step must be increased 20-50 fold, while only a small change in flow would be required with light work. It was a goal of this study to determine how muscle pyruvate oxidation was regulated during exercise.

The initial goal was to determine to what extent the increased muscle pyruvate oxidation with exercise was due to increased formation of PDH$_a$. The assay of PDH$_a$ activity was not a major problem and is discussed elsewhere. The major difficulty was the quantitation of muscle $CO_2$ production derived from pyruvate. One method could involve determining muscle glycogen concentration changes and the muscle balance of key metabolic fuels by sampling femoral, arterial and venous blood samples if the leg blood flow is known. In this manner, if an exercising muscle mass was assumed, it would be possible to determine the balance of the key metabolites across the muscle vascular bed and
calculate the rate of pyruvate oxidation. While this technique is possible and has been used,212,213 it was generally felt that such an approach could not be justified ethically. The other quantitative method would involve the use of a pyruvate-$^{14}$C tracer to measure the body pyruvate turnover. A major problem with this approach is that body pyruvate utilization does not necessarily equal muscle pyruvate oxidation since pyruvate can be metabolized in different ways in many different organs.214,215 In addition, it would be difficult to measure quantitative changes in muscle pyruvate oxidation because the exchange between the muscle generated Co$_2$ and the bicarbonate pool would introduce a delay of at least 30 min.216-218

Because of these problems in quantitating the rate of muscle pyruvate oxidation, an advantage was taken of the physiological observation that heavy exercise is a situation where most of the muscle Co$_2$ is derived from muscle glycogen and blood glucose.206,219 Thus, it was assumed that the increase in body Co$_2$ production during heavy exercise must have been metabolized through PDH. The relationship between calculated pyruvate oxidation and PDH$_a$ activity is summarized in Figure 30. The rate of muscle pyruvate oxidation increased about 10-15 fold while the PDH$_a$ varied from 94-126 nmol/g/min. at rest to 260 nmol/g/min. during exercise. It was unusual for PDH not to be almost fully activated during exercise.
Figure 30.

The relationship between PDH activation and calculated muscle pyruvate oxidation. The points at the bottom of the graph represent the calculated rate of muscle pyruvate oxidation and the observed PDH activity at rest. The values at the top of the graph indicate the degree of PDH activation with exercise and the calculated increase in muscle pyruvate oxidation assuming that 80% of the increase in O\textsubscript{2} consumption is due to muscle pyruvate oxidation. The curved line represents the best fit with the data. The dotted line represents the increase in pyruvate oxidation anticipated if the increased oxidation was entirely due to PDH activation. The exercise was conducted in a progressive increase in the work load. The total V\textsubscript{CO\textsubscript{2}} and \textit{V}\textsubscript{O\textsubscript{2}} was determined at 60% of the calculated \textit{V}\textsubscript{O\textsubscript{2}} max. Each point represents one subject at rest and during exercise.
It is important to note that close to 40% of the PDH$_t$ was in the active form at rest. If this reflects the situation in the muscle cell, it follows that activation of PDH alone could only increase the rate of pyruvate oxidation by 2-3 fold. The calculated increase in the rate of muscle pyruvate oxidation was at least 10-15 fold. It is possible that the latter figure could be adjusted somewhat by altering the basic assumptions. However, it is clear that the manipulation of assumptions could not reduce the increase to 2-3 fold because this would not be consistent with published observations.220,221 It follows that either PDH activation is not the primary control of pyruvate oxidation during exercise, or that there is a fundamental error in the assay of PDH$_a$. The latter possibly can be excluded for several reasons. Firstly, using the same assay it has been possible to demonstrate a dramatic decrease in PDH$_a$ activity with immobilization. Thus, there is no fundamental flaw in the assay technique that prevents the measurement of low PDH$_a$ activity using the same methods and same tissue sources. Secondly, the PDH$_a$ activity tends to be higher in the fed state.87 The subjects were all tested after a 12-14 hour fast which would tend to decrease, not increase, the resting PDH$_a$ activity.

These results suggest that skeletal muscle pyruvate oxidation during exercise is controlled by factors
other than PDH₂ formation. The formation of PDH₂ during exercise could only explain an increase of pyruvate oxidation of 2-2.5 fold whereas the actual observed increase was at least 15 fold. The interpretation of these observations is that the rate of muscle pyruvate oxidation is largely regulated by factors which modulate the activity of PDH₂. For example, it is possible that the measured activity of PDH₂ of 124 nmol/g/min at rest (Table 13), represents the activity when all cellular inhibitory factors have been diluted out during the assay. Thus, a relatively high mitochondrial free NADH/NAD⁺ ratio and other possible factors could reduce the PDH₂ activity in the cell to 10 from the measured activity of 124 nmol/g/min. During exercise a number of regulatory factors inhibiting PDH₂ at rest would decrease and result in a marked stimulatory effect on PDH₂ activity. In addition to these factors, there is formation of PDH₂ from PDH₁ by modulating the PDH kinase and PDH phosphatase activity. The combination of both mechanisms could explain the marked increase in the calculated rate of skeletal muscle pyruvate oxidation during exercise.

Some of the factors that might regulate PDH₂ activity have been explored but interpretation of these data must be cautious because it cannot be assumed that the total tissue concentration of a metabolite necessarily reflects its concentration in the mitochondria at the location of PDH.
One of the factors controlling PDH activity is the pyruvate concentration. The resting muscle pyruvate concentration is about 50 nmol/g. With heavy exercise it increased up to 500 nmol/g. If the PDH K_m for pyruvate was well above 50 nmol/ml, a substantial increase in muscle pyruvate concentration could by itself increase the rate of muscle pyruvate oxidation. When this pyruvate concentration increase is combined with the increased formation of PDH, the calculated rise in pyruvate oxidation was about 5-7 fold. These calculations assume a relatively high (Figure 31) K_m of pyruvate which has not been observed with the purified enzyme.\textsuperscript{51,73} Experiments which were subsequently obtained in the heart (Figure 32) indicate that the "observed" K_m is lower in intact muscle. If the observations in the heart apply to skeletal muscle in vivo, it is likely that the change in muscle pyruvate concentration with exercise would have a relatively minor effect on PDH activity.

It has been established that a decrease in ATP and an increase in AMP and ADP will stimulate PDH activity.\textsuperscript{164,169} This effect has to be distinguished from the known effects of adenine nucleotides on PDH kinase and PDH phosphatase which control interconvergence between PDH and PDH\textsubscript{i}. In the experiments done for this purpose, it was observed that
Figure 31.
The effect of pyruvate concentration on the active PDH activity in human skeletal muscle at rest and exercise. The graph is a schematic Michaelis-Menton plot combining the activation of PDH and pyruvate concentration. The plot assumes a $K_m$ of 0.1 μM/ml. The pyruvate concentration increased from 0.07 to 0.2 μM/g wet wt with the progressive cycle exercise.
Figure 32.
Effect of pyruvate concentration and pyruvate oxidation in perfused rat heart: Lineweaver-Burk plot is inset. Changes in pyruvate oxidation rate were determined over a range of pyruvate concentrations. The $K_m$ is indicated at 40 $\mu$M.
a significant decrease in muscle ATP with heavy exercise resulted (Table 14). These observations are consistent with the interpretation that relatively high ATP and low AMP and ADP concentrations at rest would inhibit PDH activity. During exercise, PDH would no longer be inhibited by the decrease in ATP and increase in ADP and possibly AMP. Similar experiments could have been done for other known modulators of PDH activity to see if the changes during exercise were consistent with this interpretation. These studies are now under way.

In summary, there is evidence that skeletal muscle pyruvate oxidation during exercise is regulated largely by factors regulating the active PDH activity, while a relatively minor part of the pyruvate oxidation changes can be explained by conversion of PDH to PDH. In the heart, however, the situation appears to be quite different. The capacity to increase pyruvate oxidation is less than in skeletal muscle, and all the experimental manipulations used to alter heart pyruvate oxidation have the same effect on PDH formation (Figure 29). In fact, when the changes in the rate of pyruvate oxidation were correlated with PDH formation the correlation coefficient was greater than 0.92. This does not prove, however, that the heart pyruvate is not regulated by factors altering PDH activity, but it does indicate that no mechanisms other than PDH formation need be involved in order to explain the results.
It is possible that altered muscle PDH activity could be important in certain disease states because skeletal muscle is such a large "organ". To pursue this possibility further, some calculations to determine the capacity of the muscle PDH system were undertaken.

If a 70 kg athlete with a VO₂ max of 70 ml of oxygen/kg/min. is exercising at a rate utilizing 50 ml of oxygen/kg/min. with 20 kg of muscle, one obtains a pyruvate oxidation rate of about 2,000 nmol/g/min., assuming that the only muscle substrate used was carbohydrate in nature. The average PDH₄ activity in human skeletal muscle was about 310 nmol pyruvate/g/min. (most of the PDH assays were conducted at a pyruvate concentration of 20 µM based on the kinetic relationships outlined in Figure 29). The actual highest PDH activity and pyruvate concentration which was observed during exercise was about 1,100 nmol pyruvate/g/min. These calculations suggest that the capacity of the pyruvate dehydrogenase reaction may be close to the capacity of the maximal observed pyruvate oxidation in vivo. In this case, an inability to form PDH₄ could have significant effects in a variety of disease states.

In one child where there was an opportunity to study pyruvate metabolism where the clinical presentation was severe lactic acidosis, it was observed that there was a large decrease in the muscle PDH₄ and in the PDH₄ activity
(Table 17). A number of other case reports of similar disease entities have been reported. In most cases, the PDH activity is not absent, suggesting that it is not an inborn error of metabolism involving a failure to synthesize pyruvate dehydrogenase. It is possible that the decrease in PDH activity was secondary to some other problem. This is especially pertinent as it relates to other physiological situations we have studied and are discussed later. (Tables 18 and 19)

In a study involving normal young male athletes, it was demonstrated that an aerobic type training program did not change the muscle PDH activity but substantially increased the PDH activity. When the muscle groups were immobilized the PDH activity did not change but the PDH dropped substantially. In one subject where a fracture occurred requiring immobilization, the PDH activity dropped dramatically from a normal of 110 to 25 nmol/g/min. These observations indicate that immobilization or the training programme does not alter the total capacity for PDH activity, but substantially alters the amount of PDH in the active form. It is possible that under a variety of medical or surgical conditions that the associated immobilization results in a substantial reduction in PDH activity. This, in itself, may not present any significant problem, unless specific metabolic stress is applied. For example, how would
Table 17

Muscle PDH Activity

In a Child With Severe Lactic Acidosis

<table>
<thead>
<tr>
<th></th>
<th>PDH$_a$</th>
<th>PDH$_t$</th>
<th>A:T %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (4)</td>
<td>110 ± 4</td>
<td>308 ± 2</td>
<td>37</td>
</tr>
<tr>
<td>Baby AM</td>
<td>12</td>
<td>44</td>
<td>27</td>
</tr>
</tbody>
</table>

Legend: The 8 week old infant presented with severe metabolic acidosis. The entire anion gap could be accounted for by lactate (20-31 mM). The controls were normal adult male subjects. All biopsies were obtained from the vastus lateralis muscle group.
such patients respond when large amounts of glucose were administered? It is possible that the glucose would enter the cell, be partially metabolized and subsequently be converted to lactate because of the inability to decarboxylate pyruvate. This could explain increased susceptibility to lactic acidosis under a variety of medical conditions in which immobilization is a major feature. It is recognized that circulatory problems by themselves would and could contribute to lactic acidosis purely on the basis of poor organ perfusion. However, the possibility that the lactic acidosis develops first, followed by dehydration and decreased cardiac function cannot be excluded.

Another general observation is that patients with severe medical or surgical problems have decreased glucose tolerance. The mechanisms for this may have never been clearly explained. It is possible that a significant or major contributing factor to this could be the inability of the muscle and perhaps other cellular systems to decarboxylate pyruvate derived from glucose.

It is difficult at the present time to know the significance of these generalizations. However, one cannot readily dismiss these possibilities since the capacity for pyruvate decarboxylation seems to have very little reserve based on the calculations in skeletal muscle. This does appear to be a unique position for enzyme systems, since
most regulatory enzymes are present in concentrations that would facilitate flux through the appropriate pathway higher than is normally observed.

Insulin and epinephrine have been shown to be important hormonal factors regulating the interconversion of PDH$_i$ and PDH$_a$. In studies, outlined later in the heart (Figures 20 and 14), it was demonstrated that insulin and epinephrine resulted in activation of heart PDH. In other reported studies in the isolated fat cell, epinephrine decreased PDH$_a$ activity dramatically. Insulin in the fat cell results in complete activation of PDH. The mechanisms by which the hormones exert their effect is not clear. On the basis of the studies in the heart, it would appear clearly that cyclic AMP is not an important factor regulating interconversion of PDH$_i$ and PDH$_a$. Thus, epinephrine resulted in complete activation of PDH with a parallel increase in the cAMP concentration. Insulin resulted in PDH activation that followed a similar time course but the cAMP concentration under these conditions decreased. (Figures 15 and 21) Other investigators pursuing a similar approach have not been able to demonstrate the mechanism by which these hormones exert their effect on PDH activation and inactivation.

Therefore, in the following studies, the possible role of hormones in regulating skeletal muscle PDH activation
was pursued in several ways. In the first series of studies the femoral nerve was stimulated unilaterally and the extent of PDH activation was determined bilaterally (Figure 13). The muscle PDH was activated in the stimulated leg while no activation was observed in the contralateral leg. If the primary mechanism for muscle PDH activation was hormonal, one would have expected bilateral activation occurring at the same rate. These studies were extended to a human situation where subjects exercised one leg while the other one was at rest (Figure 13). In the human study, as in the rat, muscle PDH was activated in the exercising leg while no changes were observed on the resting side. These observations strongly suggest that the physiological regulator of PDH activation is not hormonal but probably initiated by nervous impulses.

Additional studies were done in the rat to determine whether changes in voltage or frequency had any effects on PDH activation (Tables 1, 2, 6, and 8). Five volts is consistently used by investigators192,237,238 to elicit maximal nerve excitation. With regard to the effect of voltage on PDH activation, it appears from our data that voltage between 5 and 40 volts are sufficient to induce almost 100% activation of PDH. However, the time required to reach 100% activation appears to be affected by voltage and is directly proportional to the voltage applied. Thus, at 40 volts, 90% PDH activation was reached within 15-20 sec. whereas much longer times were required for similar
activation with voltages less than 5 volts. The data do not allow us to conclude about why or how voltages greater than 5 volts can affect the rapidity of PDH activation. It is perhaps somewhat difficult to extrapolate from these animal experiments to the in vivo situations since the results in human skeletal muscle were not what one would have predicted, based on the animal studies. For example, we observed that aerobic work at about 50% \( V_{O_2} \text{max} \) resulted in fairly rapid PDH activation, whereas with more intense work, at about 140% \( V_{O_2} \text{max} \), the rate of PDH activation was slower. At present, these different results obtained with nerve stimulation in the rate and exercise in the human cannot be readily explained.

A number of studies in the last few years have demonstrated that certain mitochondrial marker enzymes, such as succinate dehydrogenase and others, increase by up to 50% following appropriate aerobic training programmes.\textsuperscript{204} In other similar studies, investigators have used morphometric techniques and have demonstrated that the number of mitochondria appear to have increased significantly with aerobic training programmes.\textsuperscript{227-229} A similar study was performed to determine whether skeletal muscle PDH activity would change during various training programmes. The rationale was that the changes might be substantially greater for PDH because it is likely that the key enzyme regulating mitochondrial metabolism is from carbohydrate-derived
substrates. In the aerobic running training programme for rats, it was observed that the PDH_a portion increased but no changes in the PDH_t activity was observed. Essentially the same results were obtained with weight training in humans. A very small number of competitive athletes were also tested for PDH concentrations and the results were essentially the same. (Table 18). While the VO_2 max was much higher in the competitive athletes than in the matched controls, the muscle PDH_t activity was the same. The PDH_a activity in the athletes was significantly greater, however, than that in the control subjects. These experiments suggest that aerobic training, while it may increase the activity of certain mitochondrial marker enzymes, does not increase the activity or amount of PDH_t present in skeletal muscle. The PDH_a activity is invariably higher in the muscle of trained subjects. The physiological significance of this is not clear at the present time. The earlier calculations (p. 145) indicating that the aerobic capacity is very close to the measured PDH_a activity in muscle suggests that under both trained and untrained conditions the regulation of pyruvate oxidation in skeletal muscle is largely controlled by factors regulating the PDH_a activity. There clearly is activation of PDH during exercise but the contribution this makes to increasing the capacity of pyruvate oxidation in muscle appears to be relatively small.
Trained carveren and two trained distance runners.

Education students. The competitive athletes were two well
number of subjects. The non-athlete controls were physical
in the "methods". The number in brackets refers to the
procedures at rest and during essay were conducted as outlined
Legend:

<table>
<thead>
<tr>
<th></th>
<th>V02 max was determined as outlined in the &quot;methods&quot;. Muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>71 + 4</td>
</tr>
<tr>
<td>309 + 15</td>
<td>215</td>
</tr>
<tr>
<td>41</td>
<td>47 + 3</td>
</tr>
<tr>
<td>304 + 9</td>
<td>124</td>
</tr>
<tr>
<td>44</td>
<td></td>
</tr>
</tbody>
</table>

Competition athletes (4)

Non-athlete controls (4)

%       (1 min/40 kg/min)  (1 min/40 kg/min)

A: 5

V02 max

Muscle PII activity in competitive athletes

Table 18
3. Heart Muscle

The major goal of these studies was to determine whether changes in pyruvate oxidation in the heart was entirely regulated by endocrine conversion (interconversion) of PDH$_i$ and PDH$_a$, unlike skeletal muscle. Heart is unique in that it cannot depend on anaerobic sources of energy for significant periods of time. It is different in other respects in that the range of oxygen consumption is substantially less than in skeletal muscle. Because at least 25% of the total pyruvate dehydrogenase is in the active form, it is difficult to see how pyruvate flow could increase by a factor of 10 or 20 on the basis of interconversion of PDH$_a$ and PDH$_i$. The heart with the smaller range of oxidative metabolism could be regulated only by interconversion of the two enzyme forms because of the smaller range of oxidative capacity.

The perfused rat heart was used as a model because this permitted better control of all the variables. The general nature of the experiments involved the use of a variety of agents which have been demonstrated to affect the rate of either pyruvate or glucose oxidation. The anticipation was that these would be modulated by PDH activation and in this way information could be obtained about the significance of PDH activation versus the regulation of PDH$_a$ by substrates, products, and allosteric factors.
In the individual experiments it was observed that activation of PDH occurred with epinephrine and insulin. (Figures 14 and 20) Octanoic acid and propranolol decreased PDH activity. (Figures 18 and 23) Additions of higher concentrations of pyruvate above 50 μM, resulted in rapid activation of PDH. (Figures 25 and 27) In all these studies the change in pyruvate oxidation was paralleled by the amount of PDH\textsubscript{a} formed. When the rate of heart pyruvate oxidation was correlated with the change in PDH\textsubscript{a} activity, a very close correlation between the two was observed. The correlation coefficient was greater than 0.92, suggesting that any deviation from this correlation probably represented experimental error. Based on these correlations, one is tempted to conclude that the alteration in pyruvate oxidation was mediated by changes in PDH\textsubscript{a} formation. While it is recognized that such correlations do not prove that PDH\textsubscript{a} formation initiated the increase in pyruvate oxidation, it does indicate that one does not have to invoke any explanations other than PDH\textsubscript{a} formation in the change of pyruvate oxidation in the perfused rat heart.

In order to pursue the mechanisms of heart PDH activation further, the rate of PDH\textsubscript{a} formation, heart pyruvate oxidation, and changes in heart cAMP concentration were determined. Epinephrine had a marked stimulatory effect on PDH\textsubscript{a} formation and a comparable increase in the
rate of pyruvate oxidation. The muscle cAMP concentration increased substantially and temporally with PDHₐ formation. When propranolol was added with epinephrine, the rate of pyruvate oxidation was decreased to the same degree as the decrease in PDHₐ activity. The cAMP concentration was still increased but was substantially less than with epinephrine alone. These results are consistent with cAMP playing a role as a second messenger in activating PDH. However, other experiments done with insulin, indicate that PDH was activated, the rate of pyruvate oxidation was increased, but the heart cAMP concentration was decreased. The results obtained with insulin in conjunction with those obtained with epinephrine indicate that hormonal activation of PDH can occur independent of changes in the cAMP concentration. These observations are consistent with studies by Reed, Huch, Denton and Jungas,₈,₉,₅₁,₉₉ who were unable to demonstrate any effect of cAMP on PDH/kinase or PDH phosphatase activity. Some earlier experiments in the fat and liver cells suggested that cAMP may play a role in PDH activation,₄₈,₁₁₁,₁₁₂ however, subsequent experiments in the same cell systems have failed to establish an important role for cAMP in PDH activation and inactivation.₉,₂₆ ⁴₉,₁₀₁,₁₀₃,₁₀₈

In addition to the hormonal effects on PDH activation in the heart, it seems clear that high concentrations of
pyruvate result in a rapid PDH activation. To what extent these effects represent regulation of the physiological nature is not clear. It would appear that these may not be that important since the plasma pyruvate concentration rarely increases to concentrations higher than 100 μM.

Earlier studies in the perfused rat heart attempted to separate the effects of epinephrine and other hormones in terms of its known effects on contractility and metabolic events.\textsuperscript{161,230,231} The perfused rat heart model used in these experiments does not permit definitive conclusions to be made on this point since the heart was essentially a non-working model. However, an indirect assessment of the presumed role of contractility with this direct metabolic effect can be assessed by comparing the degree of PDH activation, pyruvate oxidation and oxygen consumption under the various experimental conditions. (Table 19) Epinephrine resulted in marked increases in pyruvate oxidation, PDH activation, as well as a significant increase in the rate of oxygen consumption. Insulin resulted in very similar increases in pyruvate oxidation and PDH activation, but had very little effect on oxygen consumption. High concentrations of pyruvate resulted in marked increases in the rate of pyruvate oxidation and active PDH formation. However, the oxygen consumption decreased. These observations suggest that the metabolic effects on PDH activation and pyruvate
The values represent S.E.M. from flow rate and the pH. The number in parentheses refer to the "Methods". The O₂ consumption was calculated as the difference in the "Methods". The pyruvate oxidation, PMH and pH in the "Methods" were all determined as the number of observations.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>0:00</th>
<th>4:00</th>
<th>8:00</th>
<th>12:00</th>
<th>16:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (8)</td>
<td>5604</td>
<td>476</td>
<td>526</td>
<td>432</td>
<td>476</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>400</td>
<td>324</td>
<td>324</td>
<td>324</td>
<td>324</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1500</td>
<td>171</td>
<td>171</td>
<td>171</td>
<td>171</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>1220</td>
<td>166</td>
<td>166</td>
<td>166</td>
<td>166</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
<td>458</td>
</tr>
<tr>
<td>Proportion (8)</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
<td>682</td>
</tr>
</tbody>
</table>

- **PMH**: Pyruvate Oxidation
- **Pyruvate Oxidation**: Oxidation of Pyruvate
- **PMH**: Pyruvate Oxidation
- **O₂ Consumption**: O₂ Consumption

**Table 1.**

The values represent S.E.M. from flow rate and the pH. The number in parentheses refer to the "Methods". The O₂ consumption was calculated as the difference in the "Methods". The pyruvate oxidation, PMH and pH in the "Methods" were all determined as the number of observations.
oxidation can occur independently of any changes in the rate of heart oxygen consumption. While this does not prove that PDH activation and pyruvate oxidation occur independently of contractility, it suggests that there may be separate effects of the various agents.

Insulin in the perfused heart like epinephrine, stimulated PDH activity and in a parallel way stimulated pyruvate oxidation. (Figures 14 and 20) The mechanism by which insulin activates PDH is unknown. Recently it has been demonstrated that insulin had no effect on PDH phosphatase in diabetic heart \cite{184, 232, 233} suggesting that insulin may have an effect on the PDH kinase activity. Direct evidence for this is not available. The effect of insulin on PDH activation in the heart is essentially the same as observed in adipose tissue with or without added glucose. In fat cells, insulin increases lipogenesis from pyruvate \cite{98, 99, 101, 109} suggesting that one of the major effects of insulin is the stimulation of triglyceride formation from pyruvate. The heart has a relatively low rate of lipogenesis, suggesting that insulin in the heart must have a major effect on pyruvate oxidation rather than on lipogenesis.

It is possible insulin may act in some way to change the adenylate charge which in turn may activate PDH activation by decreasing the ATP:ADP ratio \cite{53, 66, 72, 73, 169, 180}.\footnotetext{184, 232, 233}
It seems unlikely that this would be the major regulatory mechanism by the way insulin works, as the ATP:ADP ratio has not been shown to change with insulin administration in the heart. On the contrary, insulin lack results in a decreased ATP:ADP ratio and decreased adenylate charge which should, if these arguments apply, result in PDH activation. Experimentally, insulin lack invariably results in PDH activation.

The PDH activity in the rat heart homogenate was not influenced by a 24 or 48 hr starvation period, however, the PDH was considerably decreased during the same starvation period. (Table 2Q) The inactivation suggests that the activity changes are hormonally or nutritionally regulated. Insulin lack, increased plasma FFA could be responsible. Most information has been primarily carried out on the regulation of increased fat oxidation and, therefore, the effects could possibly be mediated by this mechanism. The experiments in vitro suggest that the increase in the supply of FFA can lead to an increased phosphorylation of PDH in heart, liver, and kidney. 70,163,235 Perfusion of isolated rat heart with acetoacetate showed similar effects. 163 Insulin has been shown to act directly on adipose tissue 105,107 and on liver. 157 As phosphorylation is diminished in these tissues the PDH is greatly stimulated. As insulin has also exerted a stimulatory action in the heart, in this work,
The legend: The activity of PDH and PPi in rat heart of normal fed rats, 18-24 hr. starved rats and 48 hr. starved rats.

<table>
<thead>
<tr>
<th>Group</th>
<th>Activity (nmol/min)</th>
<th>ppm</th>
<th>% of normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>48 hr. start (12)</td>
<td>91</td>
<td>480 ± 149</td>
</tr>
<tr>
<td>2a</td>
<td>18-24 hr. starve (12)</td>
<td>168</td>
<td>282 ± 178</td>
</tr>
<tr>
<td>3a</td>
<td>Fed and 12th (12)</td>
<td>73</td>
<td>1469 ± 483</td>
</tr>
</tbody>
</table>

In various stages of starvation

Rat heart PDH activity

Table 20
insulin lack seems a likely candidate for producing the changes. The effects of insulin may be more widespread than those found in the results and the current literature. The degree of inactivation in the heart with starvation may be, therefore, directly due to the drop in insulin concentration in starvation. Of course, other factors may be responsible for the decrease in PDH$_2$ activity.
BIBLIOGRAPHY


